Free CME from PeerView
Continuing Pharmacy Education (CPE) Activities
Taking the Front Seat in Metastatic Melanoma Care: Guidance on Using PD-1/LAG-3 Platforms as Modern First-Line Options
StartThis activity expired on March 10, 2025; credit is no longer available.
Taking the Front Seat in Metastatic Melanoma Care: Guidance on Using PD-1/LAG-3 Platforms as Modern First-Line Options
Media: Enduring Material
Activity Release Date: March 11, 2024
Activity Expiration Date: March 10, 2025
Time to Complete Activity: 30 minutes
Activity Description
Immunotherapy is now the centerpiece of modern, highly effective care for
malignant melanoma. The most recent development in the immunotherapy
revolution has centered on the validation of fixed-dose PD-1 and LAG-3
inhibitor combinations as an effective and safe frontline option for patients
requiring treatment for advanced disease. This has raised a number of
clinical questions related to the integration of PD-1/LAG-3 platforms into
treatment plans (alongside other immune combinations) and the role of
single-agent therapy.
This expert-led activity utilizes case-based teaching and short lectures to address these questions and provide guidance on incorporating the latest evidence on PD-1/LAG-3 therapy into practice, with the goal of illustrating the modern role of immune combinations in the frontline management of metastatic melanoma. The experts discuss how different baseline factors can inform treatment decisions made by the healthcare team, review the role of immunotherapy combinations in BRAF-mutant disease, and address practical aspects associated with the safe and effective delivery of dual checkpoint blockade with PD-1/LAG-3 platforms.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, advanced practice clinicians, nurses, pharmacists, and other healthcare professionals involved in the care of patients with melanoma.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Cite updated guidelines and efficacy/safety evidence surrounding the use of newer immune-based approaches with PD-1/LAG-3 agents for unresectable and metastatic melanoma
- Implement personalized treatment plans that include PD-1/LAG-3 combination therapies for unresectable and metastatic melanoma, including in BRAF-mutant or BRAF wild-type disease
- Address practical aspects associated with newer dual checkpoint inhibition combinations, including irAE management and dosing, by working effectively in team-based care models
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Hussein Tawbi, MD, PhD
Deputy Chair and Professor
Department of Melanoma Medical Oncology
Co-Director, Andrew M. McDougall Brain Metastasis Clinic &
Program
Melanoma Medical Oncology | Investigational Cancer Therapeutics
The University of Texas MD Anderson Cancer Center
Houston, Texas
Hussein Tawbi, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Boxer Capital, LLC; Bristol Myers
Squibb; Genentech, Inc./F. Hoffmann-La Roche AG; Iovance
Biotherapeutics, Inc.; Jazz Pharmaceuticals, Inc.; Medicenna; Merck & Co.,
Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.
Grant/Research Support from Bristol Myers Squibb; Dragonfly
Therapeutics, Inc.; Genentech, Inc./F. Hoffmann-La Roche AG; GlaxoSmithKline;
Merck & Co., Inc.; Novartis Pharmaceuticals Corporation and RAPT
Therapeutics. Research Support to Institution.
Faculty/Planner
Georgina Long, AO, BSc (Hons 1, UM), PhD, MBBS, FRACP, FAHMS
Australian of the Year 2024
Co-Medical Director Melanoma Institute Australia
Professor of Melanoma Medical Oncology and Translational
Research
Melanoma Institute Australia, The University of Sydney, and Royal North
Shore & Mater Hospitals
Sydney, Australia
Georgina Long, AO, BSc (Hons 1, UM), PhD, MBBS, FRACP, FAHMS, has a
financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Agenus Inc.; Amgen Inc; Array
Biopharma; AstraZeneca; Bayer AG; BioNTech; Boehringer Ingelheim
International GmbH; Bristol Myers Squibb; Evaxion Biotech; Hexal AG
(Sandoz Company); Highlight Therapeutics S.L.; IO Biotech; Immunocore;
Innovent Biologics USA; Merck Sharpe & Dohme; Novartis; PHMR Ltd; Pierre
Fabre; Regeneron Pharmaceuticals, Inc.; Scancell; and SkylineDX
B.V.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-24-035-H01-P
Type of Activity: Knowledge
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 3/10/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their
entirety and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on March 10, 2025; credit is no longer available.
Taking the Front Seat in Metastatic Melanoma Care: Guidance on Using PD-1/LAG-3 Platforms as Modern First-Line Options
Media: Enduring Material
Activity Release Date: March 11, 2024
Activity Expiration Date: March 10, 2025
Time to Complete Activity: 30 minutes
Activity Description
Immunotherapy is now the centerpiece of modern, highly effective care for
malignant melanoma. The most recent development in the immunotherapy
revolution has centered on the validation of fixed-dose PD-1 and LAG-3
inhibitor combinations as an effective and safe frontline option for patients
requiring treatment for advanced disease. This has raised a number of
clinical questions related to the integration of PD-1/LAG-3 platforms into
treatment plans (alongside other immune combinations) and the role of
single-agent therapy.
This expert-led activity utilizes case-based teaching and short lectures to address these questions and provide guidance on incorporating the latest evidence on PD-1/LAG-3 therapy into practice, with the goal of illustrating the modern role of immune combinations in the frontline management of metastatic melanoma. The experts discuss how different baseline factors can inform treatment decisions made by the healthcare team, review the role of immunotherapy combinations in BRAF-mutant disease, and address practical aspects associated with the safe and effective delivery of dual checkpoint blockade with PD-1/LAG-3 platforms.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, advanced practice clinicians, nurses, pharmacists, and other healthcare professionals involved in the care of patients with melanoma.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Cite updated guidelines and efficacy/safety evidence surrounding the use of newer immune-based approaches with PD-1/LAG-3 agents for unresectable and metastatic melanoma
- Implement personalized treatment plans that include PD-1/LAG-3 combination therapies for unresectable and metastatic melanoma, including in BRAF-mutant or BRAF wild-type disease
- Address practical aspects associated with newer dual checkpoint inhibition combinations, including irAE management and dosing, by working effectively in team-based care models
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Hussein Tawbi, MD, PhD
Deputy Chair and Professor
Department of Melanoma Medical Oncology
Co-Director, Andrew M. McDougall Brain Metastasis Clinic &
Program
Melanoma Medical Oncology | Investigational Cancer Therapeutics
The University of Texas MD Anderson Cancer Center
Houston, Texas
Hussein Tawbi, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Boxer Capital, LLC; Bristol Myers
Squibb; Genentech, Inc./F. Hoffmann-La Roche AG; Iovance
Biotherapeutics, Inc.; Jazz Pharmaceuticals, Inc.; Medicenna; Merck & Co.,
Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.
Grant/Research Support from Bristol Myers Squibb; Dragonfly
Therapeutics, Inc.; Genentech, Inc./F. Hoffmann-La Roche AG; GlaxoSmithKline;
Merck & Co., Inc.; Novartis Pharmaceuticals Corporation and RAPT
Therapeutics. Research Support to Institution.
Faculty/Planner
Georgina Long, AO, BSc (Hons 1, UM), PhD, MBBS, FRACP, FAHMS
Australian of the Year 2024
Co-Medical Director Melanoma Institute Australia
Professor of Melanoma Medical Oncology and Translational
Research
Melanoma Institute Australia, The University of Sydney, and Royal North
Shore & Mater Hospitals
Sydney, Australia
Georgina Long, AO, BSc (Hons 1, UM), PhD, MBBS, FRACP, FAHMS, has a
financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Agenus Inc.; Amgen Inc; Array
Biopharma; AstraZeneca; Bayer AG; BioNTech; Boehringer Ingelheim
International GmbH; Bristol Myers Squibb; Evaxion Biotech; Hexal AG
(Sandoz Company); Highlight Therapeutics S.L.; IO Biotech; Immunocore;
Innovent Biologics USA; Merck Sharpe & Dohme; Novartis; PHMR Ltd; Pierre
Fabre; Regeneron Pharmaceuticals, Inc.; Scancell; and SkylineDX
B.V.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-24-035-H01-P
Type of Activity: Knowledge
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 3/10/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their
entirety and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
Exploring New Routes in Immuno-Oncology: Understanding the Role of Subcutaneous Immune Checkpoint Inhibitors & Preparing for Innovative Delivery Approaches in the Clinic
StartThis activity expired on March 7, 2025; credit is no longer available.
Exploring New Routes in Immuno-Oncology: Understanding the Role of Subcutaneous Immune Checkpoint Inhibitors & Preparing for Innovative Delivery Approaches in the Clinic
Media: Enduring Material
Activity Release Date: March 8, 2024
Activity Expiration Date: March 7, 2025
Time to Complete Activity: 30 minutes
Activity Description
In this video-based activity, an oncology expert discusses the role of subcutaneous (SC) immune checkpoint inhibitors in addressing unmet needs for the management of various solid tumors. Learn about evidence supporting SC administration of immune-oncology agents in different disease and treatment settings, and prepare to bring innovative formulations to the clinic.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, urologists, surgical oncologists, thoracic surgeons, NPs, PAs, nurses, pharmacists, and other healthcare professionals involved in the care of patients with cancer.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Explain the potential of subcutaneous routes of administration of immune checkpoint inhibitors to address unmet needs in various cancer settings
- Cite current evidence on the utilization of innovative routes of administration of immuno-oncology regimens when managing patients with cancer across different tumor and treatment settings
- Apply team-based strategies to integrate innovative formulations of immune checkpoint inhibitors in real-world practice based on the latest clinical evidence, patient preferences, and other healthcare system factors
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Prof. Laurence Albiges, MD, PhD
Full Professor of Medical Oncology
Chair of Medical Oncology Department
Gustave Roussy Institute
Villejuif, France
Prof. Laurence Albiges, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; Astellas Pharma US,
Inc.; Bristol Myers Squibb; Eisai Inc.; F. Hoffmann-La Roche Ltd; Ipsen
Biopharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.;
Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; and Pfizer
Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-24-038-H01-P
Type of Activity: Knowledge
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 3/7/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their
entirety and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on March 7, 2025; credit is no longer available.
Exploring New Routes in Immuno-Oncology: Understanding the Role of Subcutaneous Immune Checkpoint Inhibitors & Preparing for Innovative Delivery Approaches in the Clinic
Media: Enduring Material
Activity Release Date: March 8, 2024
Activity Expiration Date: March 7, 2025
Time to Complete Activity: 30 minutes
Activity Description
In this video-based activity, an oncology expert discusses the role of subcutaneous (SC) immune checkpoint inhibitors in addressing unmet needs for the management of various solid tumors. Learn about evidence supporting SC administration of immune-oncology agents in different disease and treatment settings, and prepare to bring innovative formulations to the clinic.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, urologists, surgical oncologists, thoracic surgeons, NPs, PAs, nurses, pharmacists, and other healthcare professionals involved in the care of patients with cancer.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Explain the potential of subcutaneous routes of administration of immune checkpoint inhibitors to address unmet needs in various cancer settings
- Cite current evidence on the utilization of innovative routes of administration of immuno-oncology regimens when managing patients with cancer across different tumor and treatment settings
- Apply team-based strategies to integrate innovative formulations of immune checkpoint inhibitors in real-world practice based on the latest clinical evidence, patient preferences, and other healthcare system factors
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Prof. Laurence Albiges, MD, PhD
Full Professor of Medical Oncology
Chair of Medical Oncology Department
Gustave Roussy Institute
Villejuif, France
Prof. Laurence Albiges, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; Astellas Pharma US,
Inc.; Bristol Myers Squibb; Eisai Inc.; F. Hoffmann-La Roche Ltd; Ipsen
Biopharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.;
Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; and Pfizer
Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-24-038-H01-P
Type of Activity: Knowledge
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 3/7/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their
entirety and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
Simplifying the Complicated: An Algorithmic Guide for Clinical Decision-Making in HR+, HER2- EBC and MBC
StartThis activity expired on February 17, 2025; credit is no longer available.
Simplifying the Complicated: An Algorithmic Guide for Clinical Decision-Making in HR+, HER2- EBC and MBC
Media: Enduring Material
Activity Release Date: January 18, 2024
Activity Expiration Date: February 17, 2025
Time to Complete Activity: 60 minutes
Activity Description
Despite their established role in the treatment of HR+, HER2- metastatic
breast cancer (MBC) and accumulating evidence supporting their adjuvant use
in HR+, HER2- early breast cancer (EBC), questions still surround CDK4/6
inhibitors and their use. While these agents were historically thought to be
largely similar and interchangeable, evolving data from clinical and
translational studies have shown that CDK4/6 inhibitors are not the same.
They have key differences in their chemical, biologic, pharmacologic, and
clinical features and different toxicity profiles, despite all being orally
bioavailable. Therefore, we must re-evaluate how we approach CDK4/6
inhibitors and integrate them into individualized treatment plans for
patients throughout the disease continuum, as well as consider what that
looks like in the real-world setting and how to make the most of them and
their distinct properties in the frontline setting and beyond?
In this activity, based on a recent live virtual workshop, learners receive
an in-depth, expert assessment of CDK4/6 inhibitors in HR+, HER2- EBC and
MBC, which provides the foundation for case-based discussions and tool-based
demonstrations of algorithmic decision aids designed to guide risk
assessment, candidate selection for therapy, and the optimal delivery of
treatment to reduce the risk of recurrence in individuals with HR+, HER2- EBC
before transitioning to HR+, HER2- MBC to demonstrate patient evaluation,
identify factors for prognostication, and model treatment planning,
selection, and sequencing throughout the advance disease continuum.
Additionally, the panel shares strategies to mitigate and manage common
adverse reactions associated with CDK4/6 inhibitors to improve treatment
adherence and persistence.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, advanced practice clinicians, nurses, pharmacists, and other healthcare professionals involved in the care of patients with early and metastatic breast cancer.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Identify patients with HR+, HER2- EBC and MBC via thorough assessment of clinical, pathologic, genomic, and other relevant factors
- Design individualized treatment protocols integrating CDK4/6 inhibitor therapy for patients with HR+, HER2- EBC and MBC based on the latest evidence, guidelines, and tumor/disease characteristics
- Develop team-based strategies to achieve optimal treatment adherence/persistence and prevention/mitigation of AEs associated with different CDK4/6 inhibitors in the treatment of HR+, HER2- EBC and MBC
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Erika Hamilton, MD
Chair, Breast Executive Committee
Director, Breast Cancer Research Program
Sarah Cannon Research Institute
Nashville, Tennessee
Erika Hamilton, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Arcus Biosciences, Inc.; Arvinas,
Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Deciphera Pharmaceuticals, Inc.;
Ellipses Pharma; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Greenwich
LifeSciences, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Lilly;
Loxo Oncology; Mersana Therapeutics; Novartis Pharmaceuticals Corporation;
Orum Therapeutics; Pfizer; Relay Therapeutics; Seagen Inc.; and Verascity
Science (all paid to institution).
Grant/Research Support from AbbVie Inc.; Accutar Biotechnology Inc;
Acerta Pharma; ADC Therapeutics SA; Akeso Biopharma Co., Ltd.; Amgen Inc.;
Aravive; Artios Pharma; Arvinas, Inc.; AstraZeneca; AtlasMedx, Inc.; BeiGene,
Inc.; Black Diamond Therapeutics, Inc.; Bliss Biopharmaceutical (Hangzhou)
Co., Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cascadian
Therapeutics; Clovis Oncology; Compugen; Cullinan Oncology, Inc.; Curis,
Inc.; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Dana-Farber Cancer
Institute; Dantari; Deciphera Pharmaceuticals, Inc.; Duality Biologics;
eFFECTOR Therapeutics, Inc.; Ellipses Pharma; Elucida Oncology, Inc.; EMD
Serono, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM
Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; H3 Biomedicine Inc.;
Harpoon Therapeutics; HUTCHMED (China) Limited; ImmunoGen, Inc.;
Immunomedics, Inc.; Incyte; Infinity Pharmaceuticals, Inc.; InvestisBio;
Jacobio Pharmaceuticals Group Co., Ltd.; K-Group Beta, Inc.; Karyopharm;
Lilly; Loxo Oncology; Lycera; MabSpace Biosciences Co., Ltd.; MacroGenics,
Inc.; MedImmune, LLC; Mersana Therapeutics; Merus; Millennium
Pharmaceuticals, Inc.; Molecular Templates, Inc.; Novartis Pharmaceuticals
Corporation; Nucana; Olema Oncology; OncoMed Pharmaceuticals, Inc.; Onconova
Therapeutics; Oncothyreon; ORIC Pharmaceuticals, Inc.; Orinove Inc.; Pfizer;
PharmaMar; Pieris Pharmaceuticals, Inc.; Pionyr Immunotherapeutics;
Plexxikon; Radius Health, Inc.; Regeneron Pharmaceuticals Inc.; Relay
Therapeutics; Repertoire Immune Medicines; Rgenix Inc.; Seagen Inc.; Sermonix
Pharmaceuticals; Shattuck Labs Inc.; Stemcentrx, Inc.; Sutro Biopharma, Inc.;
Syndax; Syros Pharmaceuticals, Inc.; Taiho Oncology, Inc.; TapImmune Inc;
TESARO, Inc.; Tolmar Pharmaceuticals, Inc.; Torque Therapeutics, Inc.;
Treadwell Therapeutics; Verastem, Inc.; Vincerx Pharma; zenithepigenetics;
and Zymeworks Inc. (all paid to institution).
Faculty/Planner
Komal Jhaveri, MD, FACP
Patricia and James Cayne Chair for Junior Faculty
Associate Attending
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Memorial Sloan Kettering Cancer Center/Evelyn H. Lauder Breast and Imaging
Center
New York, New York
Komal Jhaveri, MD, FACP, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Blueprint
Medicines; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Eisai Inc.; F.
Hoffmann-La Roche Ltd/Genentech, Inc.; Jounce Therapeutics, Inc.; Lilly/Loxo
Oncology; Menarini Group/Stemline Therapeutics; Novartis Pharmaceuticals
Corporation; Pfizer; Scorpion Therapeutics; Seattle Genetics, Inc. (Seagen
Inc.); Sun Pharma Advanced Research Company; and Taiho Oncology, Inc.
Grant/Research Support from ADC Therapeutics SA; AstraZeneca;
Blueprint Medicines; Debiopharm; Genentech, Inc.; Gilead Sciences, Inc.;
Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novita
Pharmaceuticals, Inc.; Pfizer; Puma Biotechnology, Inc.; Scorpion
Therapeutics; and Zymeworks Inc.
Faculty/Planner
Professor Stephen Johnston, MA, PhD
Professor of Breast Cancer Medicine & Head of Medical Oncology
Consultant Medical Oncologist & Head of The Breast Unit
The Royal Marsden NHS Foundation Trust & The Institute of Cancer
Research
Chelsea, London, United Kingdom
Professor Stephen Johnston, MA, PhD, has a financial interest/relationship
or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Lilly; Novartis
Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; and
Sanofi.
Grant/Research Support from AstraZeneca; F. Hoffmann-La Roche
Ltd/Genentech, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; and
Puma Biotechnology, Inc.
Speakers Bureau participant with AstraZeneca; Eisai Inc.; F.
Hoffmann-La Roche Ltd/Genentech, Inc.; and Pfizer.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-24-015-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 2/17/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on February 17, 2025; credit is no longer available.
Simplifying the Complicated: An Algorithmic Guide for Clinical Decision-Making in HR+, HER2- EBC and MBC
Media: Enduring Material
Activity Release Date: January 18, 2024
Activity Expiration Date: February 17, 2025
Time to Complete Activity: 60 minutes
Activity Description
Despite their established role in the treatment of HR+, HER2- metastatic
breast cancer (MBC) and accumulating evidence supporting their adjuvant use
in HR+, HER2- early breast cancer (EBC), questions still surround CDK4/6
inhibitors and their use. While these agents were historically thought to be
largely similar and interchangeable, evolving data from clinical and
translational studies have shown that CDK4/6 inhibitors are not the same.
They have key differences in their chemical, biologic, pharmacologic, and
clinical features and different toxicity profiles, despite all being orally
bioavailable. Therefore, we must re-evaluate how we approach CDK4/6
inhibitors and integrate them into individualized treatment plans for
patients throughout the disease continuum, as well as consider what that
looks like in the real-world setting and how to make the most of them and
their distinct properties in the frontline setting and beyond?
In this activity, based on a recent live virtual workshop, learners receive
an in-depth, expert assessment of CDK4/6 inhibitors in HR+, HER2- EBC and
MBC, which provides the foundation for case-based discussions and tool-based
demonstrations of algorithmic decision aids designed to guide risk
assessment, candidate selection for therapy, and the optimal delivery of
treatment to reduce the risk of recurrence in individuals with HR+, HER2- EBC
before transitioning to HR+, HER2- MBC to demonstrate patient evaluation,
identify factors for prognostication, and model treatment planning,
selection, and sequencing throughout the advance disease continuum.
Additionally, the panel shares strategies to mitigate and manage common
adverse reactions associated with CDK4/6 inhibitors to improve treatment
adherence and persistence.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, advanced practice clinicians, nurses, pharmacists, and other healthcare professionals involved in the care of patients with early and metastatic breast cancer.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Identify patients with HR+, HER2- EBC and MBC via thorough assessment of clinical, pathologic, genomic, and other relevant factors
- Design individualized treatment protocols integrating CDK4/6 inhibitor therapy for patients with HR+, HER2- EBC and MBC based on the latest evidence, guidelines, and tumor/disease characteristics
- Develop team-based strategies to achieve optimal treatment adherence/persistence and prevention/mitigation of AEs associated with different CDK4/6 inhibitors in the treatment of HR+, HER2- EBC and MBC
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Erika Hamilton, MD
Chair, Breast Executive Committee
Director, Breast Cancer Research Program
Sarah Cannon Research Institute
Nashville, Tennessee
Erika Hamilton, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Arcus Biosciences, Inc.; Arvinas,
Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Deciphera Pharmaceuticals, Inc.;
Ellipses Pharma; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Greenwich
LifeSciences, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Lilly;
Loxo Oncology; Mersana Therapeutics; Novartis Pharmaceuticals Corporation;
Orum Therapeutics; Pfizer; Relay Therapeutics; Seagen Inc.; and Verascity
Science (all paid to institution).
Grant/Research Support from AbbVie Inc.; Accutar Biotechnology Inc;
Acerta Pharma; ADC Therapeutics SA; Akeso Biopharma Co., Ltd.; Amgen Inc.;
Aravive; Artios Pharma; Arvinas, Inc.; AstraZeneca; AtlasMedx, Inc.; BeiGene,
Inc.; Black Diamond Therapeutics, Inc.; Bliss Biopharmaceutical (Hangzhou)
Co., Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cascadian
Therapeutics; Clovis Oncology; Compugen; Cullinan Oncology, Inc.; Curis,
Inc.; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Dana-Farber Cancer
Institute; Dantari; Deciphera Pharmaceuticals, Inc.; Duality Biologics;
eFFECTOR Therapeutics, Inc.; Ellipses Pharma; Elucida Oncology, Inc.; EMD
Serono, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM
Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; H3 Biomedicine Inc.;
Harpoon Therapeutics; HUTCHMED (China) Limited; ImmunoGen, Inc.;
Immunomedics, Inc.; Incyte; Infinity Pharmaceuticals, Inc.; InvestisBio;
Jacobio Pharmaceuticals Group Co., Ltd.; K-Group Beta, Inc.; Karyopharm;
Lilly; Loxo Oncology; Lycera; MabSpace Biosciences Co., Ltd.; MacroGenics,
Inc.; MedImmune, LLC; Mersana Therapeutics; Merus; Millennium
Pharmaceuticals, Inc.; Molecular Templates, Inc.; Novartis Pharmaceuticals
Corporation; Nucana; Olema Oncology; OncoMed Pharmaceuticals, Inc.; Onconova
Therapeutics; Oncothyreon; ORIC Pharmaceuticals, Inc.; Orinove Inc.; Pfizer;
PharmaMar; Pieris Pharmaceuticals, Inc.; Pionyr Immunotherapeutics;
Plexxikon; Radius Health, Inc.; Regeneron Pharmaceuticals Inc.; Relay
Therapeutics; Repertoire Immune Medicines; Rgenix Inc.; Seagen Inc.; Sermonix
Pharmaceuticals; Shattuck Labs Inc.; Stemcentrx, Inc.; Sutro Biopharma, Inc.;
Syndax; Syros Pharmaceuticals, Inc.; Taiho Oncology, Inc.; TapImmune Inc;
TESARO, Inc.; Tolmar Pharmaceuticals, Inc.; Torque Therapeutics, Inc.;
Treadwell Therapeutics; Verastem, Inc.; Vincerx Pharma; zenithepigenetics;
and Zymeworks Inc. (all paid to institution).
Faculty/Planner
Komal Jhaveri, MD, FACP
Patricia and James Cayne Chair for Junior Faculty
Associate Attending
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Memorial Sloan Kettering Cancer Center/Evelyn H. Lauder Breast and Imaging
Center
New York, New York
Komal Jhaveri, MD, FACP, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Blueprint
Medicines; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Eisai Inc.; F.
Hoffmann-La Roche Ltd/Genentech, Inc.; Jounce Therapeutics, Inc.; Lilly/Loxo
Oncology; Menarini Group/Stemline Therapeutics; Novartis Pharmaceuticals
Corporation; Pfizer; Scorpion Therapeutics; Seattle Genetics, Inc. (Seagen
Inc.); Sun Pharma Advanced Research Company; and Taiho Oncology, Inc.
Grant/Research Support from ADC Therapeutics SA; AstraZeneca;
Blueprint Medicines; Debiopharm; Genentech, Inc.; Gilead Sciences, Inc.;
Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novita
Pharmaceuticals, Inc.; Pfizer; Puma Biotechnology, Inc.; Scorpion
Therapeutics; and Zymeworks Inc.
Faculty/Planner
Professor Stephen Johnston, MA, PhD
Professor of Breast Cancer Medicine & Head of Medical Oncology
Consultant Medical Oncologist & Head of The Breast Unit
The Royal Marsden NHS Foundation Trust & The Institute of Cancer
Research
Chelsea, London, United Kingdom
Professor Stephen Johnston, MA, PhD, has a financial interest/relationship
or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Lilly; Novartis
Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; and
Sanofi.
Grant/Research Support from AstraZeneca; F. Hoffmann-La Roche
Ltd/Genentech, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; and
Puma Biotechnology, Inc.
Speakers Bureau participant with AstraZeneca; Eisai Inc.; F.
Hoffmann-La Roche Ltd/Genentech, Inc.; and Pfizer.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-24-015-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 2/17/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
From Resistance to Resilience in R/R CLL: Sequencing Strategies for Achieving Effective Continuous Care
StartThis activity expired on February 16, 2025; credit is no longer available.
From Resistance to Resilience in R/R CLL: Sequencing Strategies for Achieving Effective Continuous Care
Media: Enduring Material
Activity Release Date: January 17, 2024
Activity Expiration Date: February 16, 2025
Time to Complete Activity: 60 minutes
Activity Description
Can you move from resistance to resilience with BTK inhibitors (BTKi) in relapsed/refractory chronic lymphocytic leukemia (CLL)? Learn how to overcome the well-recognized barriers—including therapeutic intolerance and disease progression—to effective sequential care by joining CLL experts in this case-based educational program. In this activity, developed in collaboration with CLL Society, the experts provide guidance on integrating new sequential BTKi options into everyday clinical practice and share patient scenarios designed to showcase skills that can help overcome medical challenges associated with continuous BTKi therapy over multiple lines of treatment. Don’t miss this opportunity to get back to resilient care with BTKi options in CLL!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, NPs, PAs, nurses, pharmacists, and other care team professionals involved in the management of patients with R/R CLL.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the mechanistic, selectivity, and safety differences among covalent and non-covalent BTKi, including off-target effects, therapeutic intolerance, and mechanisms of BTK resistance
- Implement best practices for capturing relevant prognostic factors, disease progression, and therapeutic intolerance to guide treatment planning with BTKi in R/R CLL
- Formulate effective sequential treatment plans with BTKi strategies in CLL based on current evidence, prognostic information, and other patient- and disease-specific factors
- Employ team-based approaches to address practical aspects of CLL care when using BTKi, including care coordination, formulary planning, patient education, dosing, and management of treatment-related AEs
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Meghan C. Thompson, MD
Assistant Attending L1, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, New York
Meghan C. Thompson, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Lilly/Loxo
Oncology, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.
Grant/Research Support from AbbVie; AstraZeneca;
BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics.
Research funding goes to Institution.
Co-Chair/Planner
Catherine C. Coombs, MD
Associate Clinical Professor
University of California, Irvine
Orange, California
Catherine C. Coombs, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Allogene
Therapeutics; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen
Pharmaceuticals, Inc.; Lilly; MEI Pharma, Inc.; Mingsight Pharmaceuticals,
Inc.; and Octapharma USA, Inc.
Grant/Research Support from Lilly.
Speaker for AbbVie Inc.; AstraZeneca; BeiGene,
Inc.; and Genentech, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-24-011-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 2/16/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are
required in their entirety as well as your Board Unique ID number, DOB
(MM/DD), and a score of 75% or higher is needed to obtain MOC/CC
credit.
For nurses, the post-test and evaluation form are required in
their entirety and a score of 75% or higher is needed to obtain Nursing
Continuing Professional Development (NCPD) credit. There are no prerequisites
and there is no fee to participate in this activity or to receive NCPD
credit. Statements of Credit are awarded upon successful completion of the
post-test and evaluation form.
For pharmacists, upon receipt of the completed activity
evaluation form, you will receive an email from email@email.peerviewpress.com
within 2 weeks with a link and directions to submit your credit to the NABP
CPE Monitor Service. PVI, PeerView Institute for Medical Education, will
accept your completed evaluation form for up to 30 days and will report your
participation to the NABP only if you provide your NABP e-Profile number and
date of birth. Within 6 weeks, you can view your participation record at the
NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on February 16, 2025; credit is no longer available.
From Resistance to Resilience in R/R CLL: Sequencing Strategies for Achieving Effective Continuous Care
Media: Enduring Material
Activity Release Date: January 17, 2024
Activity Expiration Date: February 16, 2025
Time to Complete Activity: 60 minutes
Activity Description
Can you move from resistance to resilience with BTK inhibitors (BTKi) in relapsed/refractory chronic lymphocytic leukemia (CLL)? Learn how to overcome the well-recognized barriers—including therapeutic intolerance and disease progression—to effective sequential care by joining CLL experts in this case-based educational program. In this activity, developed in collaboration with CLL Society, the experts provide guidance on integrating new sequential BTKi options into everyday clinical practice and share patient scenarios designed to showcase skills that can help overcome medical challenges associated with continuous BTKi therapy over multiple lines of treatment. Don’t miss this opportunity to get back to resilient care with BTKi options in CLL!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, NPs, PAs, nurses, pharmacists, and other care team professionals involved in the management of patients with R/R CLL.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the mechanistic, selectivity, and safety differences among covalent and non-covalent BTKi, including off-target effects, therapeutic intolerance, and mechanisms of BTK resistance
- Implement best practices for capturing relevant prognostic factors, disease progression, and therapeutic intolerance to guide treatment planning with BTKi in R/R CLL
- Formulate effective sequential treatment plans with BTKi strategies in CLL based on current evidence, prognostic information, and other patient- and disease-specific factors
- Employ team-based approaches to address practical aspects of CLL care when using BTKi, including care coordination, formulary planning, patient education, dosing, and management of treatment-related AEs
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Meghan C. Thompson, MD
Assistant Attending L1, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, New York
Meghan C. Thompson, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Lilly/Loxo
Oncology, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.
Grant/Research Support from AbbVie; AstraZeneca;
BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics.
Research funding goes to Institution.
Co-Chair/Planner
Catherine C. Coombs, MD
Associate Clinical Professor
University of California, Irvine
Orange, California
Catherine C. Coombs, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Allogene
Therapeutics; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen
Pharmaceuticals, Inc.; Lilly; MEI Pharma, Inc.; Mingsight Pharmaceuticals,
Inc.; and Octapharma USA, Inc.
Grant/Research Support from Lilly.
Speaker for AbbVie Inc.; AstraZeneca; BeiGene,
Inc.; and Genentech, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-24-011-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 2/16/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are
required in their entirety as well as your Board Unique ID number, DOB
(MM/DD), and a score of 75% or higher is needed to obtain MOC/CC
credit.
For nurses, the post-test and evaluation form are required in
their entirety and a score of 75% or higher is needed to obtain Nursing
Continuing Professional Development (NCPD) credit. There are no prerequisites
and there is no fee to participate in this activity or to receive NCPD
credit. Statements of Credit are awarded upon successful completion of the
post-test and evaluation form.
For pharmacists, upon receipt of the completed activity
evaluation form, you will receive an email from email@email.peerviewpress.com
within 2 weeks with a link and directions to submit your credit to the NABP
CPE Monitor Service. PVI, PeerView Institute for Medical Education, will
accept your completed evaluation form for up to 30 days and will report your
participation to the NABP only if you provide your NABP e-Profile number and
date of birth. Within 6 weeks, you can view your participation record at the
NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
Hitting the Benchmarks in mCRC: A Precision Medicine Quality Initiative for the Care Team
StartThis activity expired on January 11, 2025; credit is no longer available.
Hitting the Benchmarks in mCRC: A Precision Medicine Quality Initiative for the Care Team
Media: Enduring Material
Activity Release Date: January 12, 2024
Activity Expiration Date: January 11, 2025
Time to Complete Activity: 45 minutes
Activity Description
In this modern era of precision oncology, several therapies targeting pathways that contribute to metastatic colorectal cancer (mCRC) pathogenesis have emerged, including therapies targeting EGFR, VEGF, and the BRAF kinase. Selecting upfront and sequential treatment by considering patient- and tumor-related factors is key to informed shared decision-making and maximizing clinical benefit for patients. This activity features an expert overview of the significance of tumor sidedness in patients with mCRC, how to effectively utilize molecular testing to determine an appropriate course of treatment, and sequencing strategies across the mCRC spectrum.
Target Audience
This activity has been designed to meet the educational needs of oncologists, pathologists, radiologists, oncology nurses, nurse practitioners, physician assistants, pharmacists, and other clinicians involved in the care of patients with mCRC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Implement tumor genotyping and evaluation of tumor sidedness at mCRC diagnosis based on current evidence, guideline recommendations, and an understanding of the mechanistic rationale
- Formulate personalized mCRC treatment plans with targeted therapies that are driven by molecular findings and primary tumor localization and supported by the latest evidence and guideline recommendations using a team-based approach
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
John L. Marshall, MD
Director, The Ruesch Center for the Cure of GI Cancers
Frederick P. Smith Endowed Chair
Chief Medical Officer
Lombardi Comprehensive Cancer Center
Georgetown University Medical Center
Washington, District of Columbia
John L. Marshall, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Arcos; AstraZeneca;
Bayer Corporation; Caris Life Sciences; Merck & Co., Inc.; Oradose;
Pfizer; Seagen Inc.; Taiho Oncology, Inc.; Takeda Pharmaceutical
Company Limited; and Zcurex.
Grant/Research Support from Arcos; AstraZeneca; Bayer
Corporation; Caris Life Sciences; Merck & Co., Inc.; Oradose;
Pfizer; Seagen Inc.; Taiho Oncology, Inc.; Takeda Pharmaceutical
Company Limited; and Zcurex.
Other Financial or Material Support Executive role
for Indivumed GmbH.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Continuing Certification Statement
The activity titled “Hitting the Benchmarks in mCRC: A Precision Medicine Quality Initiative for the Care Team” has been registered to offer 0.75 Lifelong Learning credit in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-066-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 1/11/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are
required in their entirety as well as your Board Unique ID number, DOB
(MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of
75% or higher is needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in
their entirety and a score of 75% or higher is needed to obtain Nursing
Continuing Professional Development (NCPD) credit. There are no prerequisites
and there is no fee to participate in this activity or to receive NCPD
credit. Statements of Credit are awarded upon successful completion of the
post-test and evaluation form.
For pharmacists, upon receipt of the completed activity
evaluation form, you will receive an email from email@email.peerviewpress.com
within 2 weeks with a link and directions to submit your credit to the NABP
CPE Monitor Service. PVI, PeerView Institute for Medical Education, will
accept your completed evaluation form for up to 30 days and will report your
participation to the NABP only if you provide your NABP e-Profile number and
date of birth. Within 6 weeks, you can view your participation record at the
NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/CC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on January 11, 2025; credit is no longer available.
Hitting the Benchmarks in mCRC: A Precision Medicine Quality Initiative for the Care Team
Media: Enduring Material
Activity Release Date: January 12, 2024
Activity Expiration Date: January 11, 2025
Time to Complete Activity: 45 minutes
Activity Description
In this modern era of precision oncology, several therapies targeting pathways that contribute to metastatic colorectal cancer (mCRC) pathogenesis have emerged, including therapies targeting EGFR, VEGF, and the BRAF kinase. Selecting upfront and sequential treatment by considering patient- and tumor-related factors is key to informed shared decision-making and maximizing clinical benefit for patients. This activity features an expert overview of the significance of tumor sidedness in patients with mCRC, how to effectively utilize molecular testing to determine an appropriate course of treatment, and sequencing strategies across the mCRC spectrum.
Target Audience
This activity has been designed to meet the educational needs of oncologists, pathologists, radiologists, oncology nurses, nurse practitioners, physician assistants, pharmacists, and other clinicians involved in the care of patients with mCRC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Implement tumor genotyping and evaluation of tumor sidedness at mCRC diagnosis based on current evidence, guideline recommendations, and an understanding of the mechanistic rationale
- Formulate personalized mCRC treatment plans with targeted therapies that are driven by molecular findings and primary tumor localization and supported by the latest evidence and guideline recommendations using a team-based approach
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
John L. Marshall, MD
Director, The Ruesch Center for the Cure of GI Cancers
Frederick P. Smith Endowed Chair
Chief Medical Officer
Lombardi Comprehensive Cancer Center
Georgetown University Medical Center
Washington, District of Columbia
John L. Marshall, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Arcos; AstraZeneca;
Bayer Corporation; Caris Life Sciences; Merck & Co., Inc.; Oradose;
Pfizer; Seagen Inc.; Taiho Oncology, Inc.; Takeda Pharmaceutical
Company Limited; and Zcurex.
Grant/Research Support from Arcos; AstraZeneca; Bayer
Corporation; Caris Life Sciences; Merck & Co., Inc.; Oradose;
Pfizer; Seagen Inc.; Taiho Oncology, Inc.; Takeda Pharmaceutical
Company Limited; and Zcurex.
Other Financial or Material Support Executive role
for Indivumed GmbH.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Continuing Certification Statement
The activity titled “Hitting the Benchmarks in mCRC: A Precision Medicine Quality Initiative for the Care Team” has been registered to offer 0.75 Lifelong Learning credit in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-066-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 1/11/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are
required in their entirety as well as your Board Unique ID number, DOB
(MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of
75% or higher is needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in
their entirety and a score of 75% or higher is needed to obtain Nursing
Continuing Professional Development (NCPD) credit. There are no prerequisites
and there is no fee to participate in this activity or to receive NCPD
credit. Statements of Credit are awarded upon successful completion of the
post-test and evaluation form.
For pharmacists, upon receipt of the completed activity
evaluation form, you will receive an email from email@email.peerviewpress.com
within 2 weeks with a link and directions to submit your credit to the NABP
CPE Monitor Service. PVI, PeerView Institute for Medical Education, will
accept your completed evaluation form for up to 30 days and will report your
participation to the NABP only if you provide your NABP e-Profile number and
date of birth. Within 6 weeks, you can view your participation record at the
NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/CC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBC
StartThis activity expired on February 9, 2025; credit is no longer available.
Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBC
Media: Enduring Material
Activity Release Date: January 10, 2024
Activity Expiration Date: February 9, 2025
Time to Complete Activity: 60 minutes
Activity Description
The standard of care for patients with HR+, HER2- locally advanced unresectable or metastatic breast cancer (MBC) in the first-line setting involves endocrine therapy in combination with a CDK4/6 inhibitor. However, questions persist regarding the optimal use of each CDK4/6 inhibitor in first- and later-line settings. Ongoing research, fortunately, is providing new insights into the use of CDK4/6 inhibitors. Additionally, a number of investigational therapies with the potential to change clinical practice are showing great promise, with some recently approved in the metastatic setting. These investigational therapies include novel oral SERDs, ATK inhibition, and antibody–drug conjugates, such as those targeting HER2 and TROP2. With these therapies proving their clinical potential, it is essential to learn how to best integrate them into the current treatment arsenal. Furthermore, various patient- and disease-related factors such as age, HR status, metastatic sites, visceral involvement, endocrine resistance, tumor grade, disease-free interval, and molecular profile must be considered for optimal individualized therapy as well. In this PeerView Live virtual workshop, presented through a case-based framework, leading experts review the latest clinical evidence and provide practical strategies on navigating the complexities of clinical decision-making and selection and sequencing of therapies. The panel also addresses the nuances of treatment delivery and best practices for mitigating and managing adverse events associated with CDK4/6 inhibitors to help patients with HR+, HER2- MBC achieve the best possible outcomes.
Target Audience
This activity has been designed to meet the educational needs of oncologists, advanced practice clinicians, nurses, pharmacists, and other healthcare professionals involved in the care of patients with HR+, HER2- MBC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Evaluate the latest efficacy and safety data supporting the use of CDK4/6 inhibitors, as well as new and emerging treatment options for patients with HR+, HER2- MBC, considering their evolving roles in clinical practice
- Develop individualized treatment plans that integrate CDK4/6 inhibitor therapy for patients with HR+, HER2- MBC, based on the latest evidence, guidelines, and assessment of drug-, tumor/disease-, and patient-related factors
- Implement team-based strategies to achieve optimal treatment adherence and persistence, as well as prevent and mitigate adverse events associated with different CDK4/6 inhibitors in the management of HR+, HER2- MBC
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Director, Breast Cancer Research Program
Texas Oncology
US Oncology
Dallas, Texas
Joyce O’Shaughnessy, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Agendia;
Amgen Inc.; Aptitude Health; AstraZeneca; Bayer HealthCare Pharmaceuticals,
Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.;
Duality Biologics; Eisai Inc.; F. Hoffmann-La Roche Ltd.; G1 Therapeutics,
Inc.; Genentech, Inc.; Gilead Sciences, Inc.; GRAIL, Inc.; Halozyme, Inc.;
Heron Therapeutics, Inc.; Immunomedics, Inc.; Ipsen Biopharmaceuticals, Inc.;
Lilly; Merck & Co., Inc.; Myriad Genetics, Inc.; Nektar; Novartis
Pharmaceuticals Corporation; Ontada LLC; Pfizer; Pharmacyclics LLC; Pierre
Fabre group; prIME Oncology; Puma Biotechnology, Inc.; Samsung Bioepis;
Sanofi; Scorpion Therapeutics, Inc.; Seagen Inc.; Stemline Therapeutics,
Inc./The Menarini Group; Syndax Pharmaceuticals Inc.; Synthon; Taiho
Oncology, Inc.; and Takeda Pharmaceutical Company Limited.
Faculty/Planner
Sara M. Tolaney, MD, MPH
Chief, Division of Breast Oncology
Associate Director
Susan F. Smith Center for Women’s Cancers
Senior Physician
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Sara M. Tolaney, MD, MPH, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for 4D pharma plc; Aadi
Bioscience, Inc.; ARC Therapeutics; Artios Pharma; AstraZeneca; Bayer
HealthCare Pharmaceuticals, Inc.; BeyondSpring Pharmaceuticals Inc.;
Blueprint Medicines; Bristol Myers Squibb; CytomX Therapeutics, Inc.; Daiichi
Sankyo Inc.; eFFECTOR Therapeutics; Eisai Inc.; Exelixis, Inc.; Genentech,
Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Incyte; Jazz
Pharmaceuticals; Lilly; Merck & Co., Inc.; Myovant Sciences Ltd.; Natera;
Novartis Pharmaceuticals Corporation; Pfizer; Reveal Genomics; Sanofi;
Seattle Genetics, Inc.; Stemline Therapeutics, Inc./The Menarini
Group; Systimmune; Tango Therapeutics; Umoja Biopharma; Zentalis;
Zetagen; and Zymeworks Inc.
Grant/Research Support from AstraZeneca; Bristol Myers
Squibb; Cyclacel Pharmaceuticals, Inc.; Eisai Inc.; Exelixis, Inc.;
Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly;
Merck & Co., Inc.; NanoString Technologies Inc.; Nektar; Novartis
Pharmaceuticals Corporation; Pfizer; Sanofi; and Seattle Genetics, Inc.
Other Financial or Material Support from Steering
committee for CytomX Therapeutics, Inc. and OncXerna Therapeutics, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-24-004-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 2/9/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are
required in their entirety as well as your Board Unique ID number, DOB
(MM/DD), and a score of 75% or higher is needed to obtain MOC/CC
credit.
For nurses, the post-test and evaluation form are required in
their entirety and a score of 75% or higher is needed to obtain Nursing
Continuing Professional Development (NCPD) credit. There are no prerequisites
and there is no fee to participate in this activity or to receive NCPD
credit. Statements of Credit are awarded upon successful completion of the
post-test and evaluation form.
For pharmacists, upon receipt of the completed activity
evaluation form, you will receive an email from email@email.peerviewpress.com
within 2 weeks with a link and directions to submit your credit to the NABP
CPE Monitor Service. PVI, PeerView Institute for Medical Education, will
accept your completed evaluation form for up to 30 days and will report your
participation to the NABP only if you provide your NABP e-Profile number and
date of birth. Within 6 weeks, you can view your participation record at the
NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on February 9, 2025; credit is no longer available.
Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBC
Media: Enduring Material
Activity Release Date: January 10, 2024
Activity Expiration Date: February 9, 2025
Time to Complete Activity: 60 minutes
Activity Description
The standard of care for patients with HR+, HER2- locally advanced unresectable or metastatic breast cancer (MBC) in the first-line setting involves endocrine therapy in combination with a CDK4/6 inhibitor. However, questions persist regarding the optimal use of each CDK4/6 inhibitor in first- and later-line settings. Ongoing research, fortunately, is providing new insights into the use of CDK4/6 inhibitors. Additionally, a number of investigational therapies with the potential to change clinical practice are showing great promise, with some recently approved in the metastatic setting. These investigational therapies include novel oral SERDs, ATK inhibition, and antibody–drug conjugates, such as those targeting HER2 and TROP2. With these therapies proving their clinical potential, it is essential to learn how to best integrate them into the current treatment arsenal. Furthermore, various patient- and disease-related factors such as age, HR status, metastatic sites, visceral involvement, endocrine resistance, tumor grade, disease-free interval, and molecular profile must be considered for optimal individualized therapy as well. In this PeerView Live virtual workshop, presented through a case-based framework, leading experts review the latest clinical evidence and provide practical strategies on navigating the complexities of clinical decision-making and selection and sequencing of therapies. The panel also addresses the nuances of treatment delivery and best practices for mitigating and managing adverse events associated with CDK4/6 inhibitors to help patients with HR+, HER2- MBC achieve the best possible outcomes.
Target Audience
This activity has been designed to meet the educational needs of oncologists, advanced practice clinicians, nurses, pharmacists, and other healthcare professionals involved in the care of patients with HR+, HER2- MBC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Evaluate the latest efficacy and safety data supporting the use of CDK4/6 inhibitors, as well as new and emerging treatment options for patients with HR+, HER2- MBC, considering their evolving roles in clinical practice
- Develop individualized treatment plans that integrate CDK4/6 inhibitor therapy for patients with HR+, HER2- MBC, based on the latest evidence, guidelines, and assessment of drug-, tumor/disease-, and patient-related factors
- Implement team-based strategies to achieve optimal treatment adherence and persistence, as well as prevent and mitigate adverse events associated with different CDK4/6 inhibitors in the management of HR+, HER2- MBC
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Director, Breast Cancer Research Program
Texas Oncology
US Oncology
Dallas, Texas
Joyce O’Shaughnessy, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Agendia;
Amgen Inc.; Aptitude Health; AstraZeneca; Bayer HealthCare Pharmaceuticals,
Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.;
Duality Biologics; Eisai Inc.; F. Hoffmann-La Roche Ltd.; G1 Therapeutics,
Inc.; Genentech, Inc.; Gilead Sciences, Inc.; GRAIL, Inc.; Halozyme, Inc.;
Heron Therapeutics, Inc.; Immunomedics, Inc.; Ipsen Biopharmaceuticals, Inc.;
Lilly; Merck & Co., Inc.; Myriad Genetics, Inc.; Nektar; Novartis
Pharmaceuticals Corporation; Ontada LLC; Pfizer; Pharmacyclics LLC; Pierre
Fabre group; prIME Oncology; Puma Biotechnology, Inc.; Samsung Bioepis;
Sanofi; Scorpion Therapeutics, Inc.; Seagen Inc.; Stemline Therapeutics,
Inc./The Menarini Group; Syndax Pharmaceuticals Inc.; Synthon; Taiho
Oncology, Inc.; and Takeda Pharmaceutical Company Limited.
Faculty/Planner
Sara M. Tolaney, MD, MPH
Chief, Division of Breast Oncology
Associate Director
Susan F. Smith Center for Women’s Cancers
Senior Physician
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Sara M. Tolaney, MD, MPH, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for 4D pharma plc; Aadi
Bioscience, Inc.; ARC Therapeutics; Artios Pharma; AstraZeneca; Bayer
HealthCare Pharmaceuticals, Inc.; BeyondSpring Pharmaceuticals Inc.;
Blueprint Medicines; Bristol Myers Squibb; CytomX Therapeutics, Inc.; Daiichi
Sankyo Inc.; eFFECTOR Therapeutics; Eisai Inc.; Exelixis, Inc.; Genentech,
Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Incyte; Jazz
Pharmaceuticals; Lilly; Merck & Co., Inc.; Myovant Sciences Ltd.; Natera;
Novartis Pharmaceuticals Corporation; Pfizer; Reveal Genomics; Sanofi;
Seattle Genetics, Inc.; Stemline Therapeutics, Inc./The Menarini
Group; Systimmune; Tango Therapeutics; Umoja Biopharma; Zentalis;
Zetagen; and Zymeworks Inc.
Grant/Research Support from AstraZeneca; Bristol Myers
Squibb; Cyclacel Pharmaceuticals, Inc.; Eisai Inc.; Exelixis, Inc.;
Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly;
Merck & Co., Inc.; NanoString Technologies Inc.; Nektar; Novartis
Pharmaceuticals Corporation; Pfizer; Sanofi; and Seattle Genetics, Inc.
Other Financial or Material Support from Steering
committee for CytomX Therapeutics, Inc. and OncXerna Therapeutics, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-24-004-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 2/9/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are
required in their entirety as well as your Board Unique ID number, DOB
(MM/DD), and a score of 75% or higher is needed to obtain MOC/CC
credit.
For nurses, the post-test and evaluation form are required in
their entirety and a score of 75% or higher is needed to obtain Nursing
Continuing Professional Development (NCPD) credit. There are no prerequisites
and there is no fee to participate in this activity or to receive NCPD
credit. Statements of Credit are awarded upon successful completion of the
post-test and evaluation form.
For pharmacists, upon receipt of the completed activity
evaluation form, you will receive an email from email@email.peerviewpress.com
within 2 weeks with a link and directions to submit your credit to the NABP
CPE Monitor Service. PVI, PeerView Institute for Medical Education, will
accept your completed evaluation form for up to 30 days and will report your
participation to the NABP only if you provide your NABP e-Profile number and
date of birth. Within 6 weeks, you can view your participation record at the
NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
Getting Personal: Reassessing HIV Management to Better Individualize Treatment Across the Ages
StartThis activity expired on December 12, 2024; credit is no longer available.
Getting Personal: Reassessing HIV Management to Better Individualize Treatment Across the Ages
Media: Enduring Material
Activity Release Date: December 13, 2023
Activity Expiration Date: December 12, 2024
Time to Complete Activity: 60 minutes
Activity Description
In this activity, an expert discusses identifying barriers that threaten ending the HIV epidemic, current and emerging treatment options in HIV management, and ways to personalize treatment for patients living with HIV to improve outcomes and adherence.
Target Audience
This activity has been designed to meet the educational needs of HIV care providers, primary care providers and general practitioners, advanced practice providers, nurses, pharmacists, and other professionals involved in the care of patients living with HIV.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Identify patient barriers that may contribute to poor persistence with HIV treatment
- Counsel patients living with HIV about the benefits and flexibility of current and emerging options in treatment and the importance of remaining adherent to therapy
- Personalize treatment for patients living with HIV based on therapeutic mechanism of action, route of administration, efficacy, safety, and resistance profiles, considering each patient’s individual needs across the age span (adolescence, child-bearing years, aged >65 years)
- Implement team-based HIV management strategies that ensure health equity, access and adherence to treatment, and ongoing monitoring for resistance
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Professor Chloe Orkin
Professor of Infection and Inequities
Queen Mary University of London
Barts Health NHS Trust
London, England, United Kingdom
Professor Chloe Orkin has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; GSK; Merck
Sharp & Dohme; and ViiV Healthcare group of companies.
Grant/Research Support from Gilead Sciences, Inc. and ViiV
Healthcare group of companies.
Speaker for Gilead Sciences, Inc.; GSK; Merck Sharp & Dohme;
and ViiV Healthcare group of companies.
Patient Advocate/Planner
Shawnte' Spriggs
Shawnte' Spriggs has no financial interests/relationships or affiliations in relation to this activity.
Patient Advocate/Planner
Donald Young
Donald Young has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This program has been supported by an independent educational grant from Gilead Sciences, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-069-H02-P
Type of Activity: Knowledge
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 12/12/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on December 12, 2024; credit is no longer available.
Getting Personal: Reassessing HIV Management to Better Individualize Treatment Across the Ages
Media: Enduring Material
Activity Release Date: December 13, 2023
Activity Expiration Date: December 12, 2024
Time to Complete Activity: 60 minutes
Activity Description
In this activity, an expert discusses identifying barriers that threaten ending the HIV epidemic, current and emerging treatment options in HIV management, and ways to personalize treatment for patients living with HIV to improve outcomes and adherence.
Target Audience
This activity has been designed to meet the educational needs of HIV care providers, primary care providers and general practitioners, advanced practice providers, nurses, pharmacists, and other professionals involved in the care of patients living with HIV.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Identify patient barriers that may contribute to poor persistence with HIV treatment
- Counsel patients living with HIV about the benefits and flexibility of current and emerging options in treatment and the importance of remaining adherent to therapy
- Personalize treatment for patients living with HIV based on therapeutic mechanism of action, route of administration, efficacy, safety, and resistance profiles, considering each patient’s individual needs across the age span (adolescence, child-bearing years, aged >65 years)
- Implement team-based HIV management strategies that ensure health equity, access and adherence to treatment, and ongoing monitoring for resistance
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Professor Chloe Orkin
Professor of Infection and Inequities
Queen Mary University of London
Barts Health NHS Trust
London, England, United Kingdom
Professor Chloe Orkin has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; GSK; Merck
Sharp & Dohme; and ViiV Healthcare group of companies.
Grant/Research Support from Gilead Sciences, Inc. and ViiV
Healthcare group of companies.
Speaker for Gilead Sciences, Inc.; GSK; Merck Sharp & Dohme;
and ViiV Healthcare group of companies.
Patient Advocate/Planner
Shawnte' Spriggs
Shawnte' Spriggs has no financial interests/relationships or affiliations in relation to this activity.
Patient Advocate/Planner
Donald Young
Donald Young has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This program has been supported by an independent educational grant from Gilead Sciences, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-069-H02-P
Type of Activity: Knowledge
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 12/12/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
Equitably Empowering Our Upper GI Cancer Patients Using Plain Language Tools to Improve Outcomes With Immunotherapeutic Regimens Through Informed Shared Decision-Making
StartThis activity expired on December 12, 2024; credit is no longer available.
Equitably Empowering Our Upper GI Cancer Patients Using Plain Language Tools to Improve Outcomes With Immunotherapeutic Regimens Through Informed Shared Decision-Making
Media: Enduring Material
Activity Release Date: December 13, 2023
Activity Expiration Date: December 12, 2024
Time to Complete Activity: 30 minutes
Activity Description
The establishment of immunotherapy-based regimens in the modern treatment
paradigm for upper GI Cancers, including gastric and gastroesophageal
junction (GEJ) cancers, is placing increased importance on close
collaboration between the clinical care team and patients and caregivers, to
promote engagement in a process of informed shared decision-making (SDM) when
selecting treatment plans that are tailored to patient-specific needs,
values, and preferences.
In this PeerView activity, an oncologist, who is an expert in GI cancers,
will present practice-changing evidence for integrating immunotherapy
approaches into treatment plans; give insights on the rationale and benefits
of engaging patients in informed shared decision-making when choosing
treatment options; and explore the available tools when making informed
shared decisions about immuno-oncology strategies as part of a team-based,
equitable management approach, using the CheckMate -649 plain language
summary as an example that can be downloaded for your use. Don’t miss this
unique opportunity to enhance your skills in patient engagement to promote
SDM in your practice!
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, nurse practitioners, physician assistants, nurses, pharmacists, and other care team professionals involved in the treatment of patients with upper GI cancers.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe current evidence-based, guideline-recommended protocols for integrating immuno-oncology approaches into treatment plans for patients with upper GI cancers across disease settings
- Explain the benefits of engaging patients with upper GI cancers in informed shared decision-making by the healthcare team when choosing a treatment option including the effects on patient engagement in the selected treatment plan
- Utilize available tools including plain language summaries when making informed shared decisions about including immuno-oncology strategies as part of a team-based, equitable management approach to upper GI malignancies
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Yelena Y. Janjigian*, MD
Professor and Chief of Gastrointestinal Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
*This activity was developed with Yelena Y. Janjigian, MD, and is not
affiliated in any capacity with Memorial Sloan Kettering Cancer Center.
Yelena Y. Janjigian*, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie, Inc.; AmerisourceBergen; Arcus
Biosciences; AskGene Pharma, Inc.; Astellas Pharma Inc.; AstraZeneca; Basilea
Pharmaceutica Ltd.; Bayer Corporation; Bristol Myers Squibb; Daiichi Sankyo
Inc.; GlaxoSmithKline; Guardant Health; Imugene Limited; Inspirna, Inc.;
Lilly; Merck & Co., Inc.; Merck Serono; Mersana Therapeutics Inc.; Pfizer;
Rgenix Inc.; Seagen Inc.; Silverback Therapeutics (ARS Pharmaceuticals) and
Zymeworks Inc.
Grant/Research Support from Arcus Biosciences; AstraZeneca; Bayer
HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Cycle for Survival;
Fred's Team; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Inspirna, Inc.;
Lilly; Merck & Co., Inc.; National Cancer Institute; Transcenta Holding; and
U.S. Department of Defense.
Stock Shareholder in Inspirna, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and no contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-073-H01-P
Type of Activity: Knowledge
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 12/12/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on December 12, 2024; credit is no longer available.
Equitably Empowering Our Upper GI Cancer Patients Using Plain Language Tools to Improve Outcomes With Immunotherapeutic Regimens Through Informed Shared Decision-Making
Media: Enduring Material
Activity Release Date: December 13, 2023
Activity Expiration Date: December 12, 2024
Time to Complete Activity: 30 minutes
Activity Description
The establishment of immunotherapy-based regimens in the modern treatment
paradigm for upper GI Cancers, including gastric and gastroesophageal
junction (GEJ) cancers, is placing increased importance on close
collaboration between the clinical care team and patients and caregivers, to
promote engagement in a process of informed shared decision-making (SDM) when
selecting treatment plans that are tailored to patient-specific needs,
values, and preferences.
In this PeerView activity, an oncologist, who is an expert in GI cancers,
will present practice-changing evidence for integrating immunotherapy
approaches into treatment plans; give insights on the rationale and benefits
of engaging patients in informed shared decision-making when choosing
treatment options; and explore the available tools when making informed
shared decisions about immuno-oncology strategies as part of a team-based,
equitable management approach, using the CheckMate -649 plain language
summary as an example that can be downloaded for your use. Don’t miss this
unique opportunity to enhance your skills in patient engagement to promote
SDM in your practice!
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, nurse practitioners, physician assistants, nurses, pharmacists, and other care team professionals involved in the treatment of patients with upper GI cancers.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe current evidence-based, guideline-recommended protocols for integrating immuno-oncology approaches into treatment plans for patients with upper GI cancers across disease settings
- Explain the benefits of engaging patients with upper GI cancers in informed shared decision-making by the healthcare team when choosing a treatment option including the effects on patient engagement in the selected treatment plan
- Utilize available tools including plain language summaries when making informed shared decisions about including immuno-oncology strategies as part of a team-based, equitable management approach to upper GI malignancies
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Yelena Y. Janjigian*, MD
Professor and Chief of Gastrointestinal Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
*This activity was developed with Yelena Y. Janjigian, MD, and is not
affiliated in any capacity with Memorial Sloan Kettering Cancer Center.
Yelena Y. Janjigian*, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie, Inc.; AmerisourceBergen; Arcus
Biosciences; AskGene Pharma, Inc.; Astellas Pharma Inc.; AstraZeneca; Basilea
Pharmaceutica Ltd.; Bayer Corporation; Bristol Myers Squibb; Daiichi Sankyo
Inc.; GlaxoSmithKline; Guardant Health; Imugene Limited; Inspirna, Inc.;
Lilly; Merck & Co., Inc.; Merck Serono; Mersana Therapeutics Inc.; Pfizer;
Rgenix Inc.; Seagen Inc.; Silverback Therapeutics (ARS Pharmaceuticals) and
Zymeworks Inc.
Grant/Research Support from Arcus Biosciences; AstraZeneca; Bayer
HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Cycle for Survival;
Fred's Team; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Inspirna, Inc.;
Lilly; Merck & Co., Inc.; National Cancer Institute; Transcenta Holding; and
U.S. Department of Defense.
Stock Shareholder in Inspirna, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and no contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-073-H01-P
Type of Activity: Knowledge
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 12/12/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care
StartThis activity expired on November 27, 2024; credit is no longer available.
Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care
Expert commentary is based on data presented at the European Society for
Medical Oncology (ESMO) Congress 2023.
PeerView is an independent publisher of conference news and medical education
programs.
Media: Enduring Material
Activity Release Date: November 28, 2023
Activity Expiration Date: November 27, 2024
Time to Complete Activity: 45 minutes
Activity Description
Emerging evidence supporting modern targeted strategies for the management
of biliary tract cancers (BTC) and gastroesophageal adenocarcinoma (GEA) has
led to the development of several agents to personalize therapy for patients
with HER2-expressing malignancies.
In collaboration with the Cholangiocarcinoma Foundation, this activity will
provide the latest updates on evolving, evidence-based practice standards for
HER2-targeting agents, including emerging data arising from the 2023 ESMO
Congress. Through a conversational exchange of ideas combined with
compelling, case-based instruction, experts will engage in discussions of
real-world patient scenarios to illustrate best practices for the management
of HER2-expressing BTC and GEA, including overcoming barriers associated with
baseline molecular testing for personalized therapy selection.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, gastrointestinal oncologists, hepatobiliary surgeons, hepatologists, gastroenterologists, physician assistants, nurse practitioners, pharmacists, and other healthcare professionals involved in the care of patients with GI cancers.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize current evidence supporting targeted agents for the management of HER2-positive GI cancers, including safety/efficacy profiles, dosing considerations, and their role in current treatment protocols
- Develop individualized treatment plans based on molecular findings, current and emerging clinical evidence, and guideline recommendations when managing patients with HER2-expressing BTC and GEA
- Integrate team-based strategies to prevent and manage well-documented adverse events associated with HER2-targeting therapies when managing patients with BTC and GEA
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Josep Tabernero, MD, PhD
Head, Medical Oncology Department, Vall d’Hebron University Hospital
(HUVH)
Director, Vall d’Hebron Institute of Oncology (VHIO)
Barcelona, Spain
Josep Tabernero, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim
International GmbH; Cardiff Oncology, Inc.; CARsgen Therapeutics; Chugai
Pharmaceutical Co., Ltd.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd;
Genentech Inc; hC Bioscience, Inc.; Ikena Oncology; Inspirna, Inc.; Lilly;
Menarini; Merck Serono; Merck Sharp & Dohme; Merus; Mirati Therapeutics Inc.;
NeoPhore; Novartis AG; Ona Therapeutics; Orion Biotechnology; Peptomyc;
Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology A/S;
Scorpion Therapeutics; Seagen; Servier; SOTIO Biotech AG; Taiho; Takeda
Oncology, ; and TOLREMO Therapeutics AG.
Stock Shareholder in Oniria Therapeutics, Alentis Therapeutics,
Pangaea Oncology and 1TRIALSP.
Co-Chair/Planner
Shubham Pant, MD
Professor
Department of Gastrointestinal Medical Oncology
Department of Investigational Cancer Therapeutics
The University of Texas MD Anderson Cancer Center
Houston, Texas
Shubham Pant, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AskGene Pharma Inc.; Boehringer
Ingelheim International GmbH; Ipsen Pharma; Janssen Pharmaceuticals, Inc.;
Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and
Zymeworks Inc.
Grant/Research Support from 4D Pharma; Amal Therapeutics; Arcus
Biosciences; Astellas Pharma Inc.; BioNTech; Boehringer Ingelheim
International GmbH; Bristol Myers Squibb; Elicio Therapeutics; Immuneering
Corporation; ImmunoMET; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Lilly;
Mirati Therapeutics, Inc.; NGM Biopharmaceuticals; Novartis Pharmaceuticals
Corporation; Pfizer; Purple Biotech; Rgenix; Xencor; and Zymeworks Inc. All
goes to Institution.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-072-H01-P
Type of Activity: Knowledge
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 11/27/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on November 27, 2024; credit is no longer available.
Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care
Expert commentary is based on data presented at the European Society for
Medical Oncology (ESMO) Congress 2023.
PeerView is an independent publisher of conference news and medical education
programs.
Media: Enduring Material
Activity Release Date: November 28, 2023
Activity Expiration Date: November 27, 2024
Time to Complete Activity: 45 minutes
Activity Description
Emerging evidence supporting modern targeted strategies for the management
of biliary tract cancers (BTC) and gastroesophageal adenocarcinoma (GEA) has
led to the development of several agents to personalize therapy for patients
with HER2-expressing malignancies.
In collaboration with the Cholangiocarcinoma Foundation, this activity will
provide the latest updates on evolving, evidence-based practice standards for
HER2-targeting agents, including emerging data arising from the 2023 ESMO
Congress. Through a conversational exchange of ideas combined with
compelling, case-based instruction, experts will engage in discussions of
real-world patient scenarios to illustrate best practices for the management
of HER2-expressing BTC and GEA, including overcoming barriers associated with
baseline molecular testing for personalized therapy selection.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, gastrointestinal oncologists, hepatobiliary surgeons, hepatologists, gastroenterologists, physician assistants, nurse practitioners, pharmacists, and other healthcare professionals involved in the care of patients with GI cancers.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize current evidence supporting targeted agents for the management of HER2-positive GI cancers, including safety/efficacy profiles, dosing considerations, and their role in current treatment protocols
- Develop individualized treatment plans based on molecular findings, current and emerging clinical evidence, and guideline recommendations when managing patients with HER2-expressing BTC and GEA
- Integrate team-based strategies to prevent and manage well-documented adverse events associated with HER2-targeting therapies when managing patients with BTC and GEA
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Josep Tabernero, MD, PhD
Head, Medical Oncology Department, Vall d’Hebron University Hospital
(HUVH)
Director, Vall d’Hebron Institute of Oncology (VHIO)
Barcelona, Spain
Josep Tabernero, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim
International GmbH; Cardiff Oncology, Inc.; CARsgen Therapeutics; Chugai
Pharmaceutical Co., Ltd.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd;
Genentech Inc; hC Bioscience, Inc.; Ikena Oncology; Inspirna, Inc.; Lilly;
Menarini; Merck Serono; Merck Sharp & Dohme; Merus; Mirati Therapeutics Inc.;
NeoPhore; Novartis AG; Ona Therapeutics; Orion Biotechnology; Peptomyc;
Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology A/S;
Scorpion Therapeutics; Seagen; Servier; SOTIO Biotech AG; Taiho; Takeda
Oncology, ; and TOLREMO Therapeutics AG.
Stock Shareholder in Oniria Therapeutics, Alentis Therapeutics,
Pangaea Oncology and 1TRIALSP.
Co-Chair/Planner
Shubham Pant, MD
Professor
Department of Gastrointestinal Medical Oncology
Department of Investigational Cancer Therapeutics
The University of Texas MD Anderson Cancer Center
Houston, Texas
Shubham Pant, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AskGene Pharma Inc.; Boehringer
Ingelheim International GmbH; Ipsen Pharma; Janssen Pharmaceuticals, Inc.;
Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and
Zymeworks Inc.
Grant/Research Support from 4D Pharma; Amal Therapeutics; Arcus
Biosciences; Astellas Pharma Inc.; BioNTech; Boehringer Ingelheim
International GmbH; Bristol Myers Squibb; Elicio Therapeutics; Immuneering
Corporation; ImmunoMET; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Lilly;
Mirati Therapeutics, Inc.; NGM Biopharmaceuticals; Novartis Pharmaceuticals
Corporation; Pfizer; Purple Biotech; Rgenix; Xencor; and Zymeworks Inc. All
goes to Institution.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-072-H01-P
Type of Activity: Knowledge
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 11/27/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
Making Choices, Improving Outcomes in Pediatric ALL: The Role of Modern Asparaginase Compounds
StartThis activity expired on November 9, 2024; credit is no longer available.
Making Choices, Improving Outcomes in Pediatric ALL: The Role of Modern Asparaginase Compounds
Media: Enduring Material
Activity Release Date: November 10, 2023
Activity Expiration Date: November 9, 2024
Time to Complete Activity: 30 minutes
Activity Description
The use of asparaginase as a component of multiagent chemotherapy has been clearly linked to optimal outcomes in pediatric acute lymphoblastic leukemia (ALL) populations. The approval of newer asparaginase formulations and dosing schedules has added to the growing collection of tools that clinicians can use to overcome challenges associated with consistent therapeutic exposure to asparaginase in ALL—but are you up to the task? This customizable, question-based activity covers the use of asparaginase compounds in pediatric ALL, the pitfalls of asparaginase discontinuation, and challenges such as hypersensitivity/silent inactivation. Test yourself and see if your choices will support the effective use of asparaginase as part of modern ALL therapy!
Target Audience
This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, advanced practice clinicians, pharmacists, other healthcare professionals, and other clinicians involved in the care of patients with acute lymphoblastic leukemia.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the latest safety and efficacy evidence and unmet medical needs related to the optimal use of asparaginase in pediatric ALL, including the role of novel Erwinia asparaginase compounds
- Develop therapeutic plans for adequate asparaginase exposure that incorporate appropriate dosing, avoidance of truncation/discontinuation, and monitoring for hypersensitivity/toxicity or silent inactivation
- Implement team-based strategies to prevent therapy discontinuation or compromised patient outcomes in pediatric ALL, such as switching to alternative asparaginase formulations
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Luke Maese, DO
Associate Professor, Pediatrics
University of Utah - Huntsman Cancer Institute
Pediatric Hematology/Oncology
Director, Clinical Trial Research Enterprise
Director, Leukemia/Lymphoma Program
Primary Children's Hospital
Salt Lake City, Utah
Luke Maese, DO, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Jazz Pharmaceuticals.
Speaker for Jazz Pharmaceuticals.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-070-H01-P
Type of Activity: Knowledge
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 11/9/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on November 9, 2024; credit is no longer available.
Making Choices, Improving Outcomes in Pediatric ALL: The Role of Modern Asparaginase Compounds
Media: Enduring Material
Activity Release Date: November 10, 2023
Activity Expiration Date: November 9, 2024
Time to Complete Activity: 30 minutes
Activity Description
The use of asparaginase as a component of multiagent chemotherapy has been clearly linked to optimal outcomes in pediatric acute lymphoblastic leukemia (ALL) populations. The approval of newer asparaginase formulations and dosing schedules has added to the growing collection of tools that clinicians can use to overcome challenges associated with consistent therapeutic exposure to asparaginase in ALL—but are you up to the task? This customizable, question-based activity covers the use of asparaginase compounds in pediatric ALL, the pitfalls of asparaginase discontinuation, and challenges such as hypersensitivity/silent inactivation. Test yourself and see if your choices will support the effective use of asparaginase as part of modern ALL therapy!
Target Audience
This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, advanced practice clinicians, pharmacists, other healthcare professionals, and other clinicians involved in the care of patients with acute lymphoblastic leukemia.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the latest safety and efficacy evidence and unmet medical needs related to the optimal use of asparaginase in pediatric ALL, including the role of novel Erwinia asparaginase compounds
- Develop therapeutic plans for adequate asparaginase exposure that incorporate appropriate dosing, avoidance of truncation/discontinuation, and monitoring for hypersensitivity/toxicity or silent inactivation
- Implement team-based strategies to prevent therapy discontinuation or compromised patient outcomes in pediatric ALL, such as switching to alternative asparaginase formulations
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Luke Maese, DO
Associate Professor, Pediatrics
University of Utah - Huntsman Cancer Institute
Pediatric Hematology/Oncology
Director, Clinical Trial Research Enterprise
Director, Leukemia/Lymphoma Program
Primary Children's Hospital
Salt Lake City, Utah
Luke Maese, DO, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Jazz Pharmaceuticals.
Speaker for Jazz Pharmaceuticals.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-070-H01-P
Type of Activity: Knowledge
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 11/9/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care
StartThis activity expired on December 9, 2024; credit is no longer available.
Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care
Media: Enduring Material
Activity Release Date: November 10, 2023
Activity Expiration Date: December 9, 2024
Time to Complete Activity: 90 minutes
Activity Description
Antibody–drug conjugates (ADCs), including those targeting HER2, HER3, and
TROP2, are an exciting new class of therapies that selectively deliver
cytotoxic payloads to cancer cells. Recent regulatory approvals have cemented
the role of ADCs in the treatment of various solid tumors, motivating further
innovation to expand their use in other tumor types and disease settings. The
new ADC era brings hope to patients with unmet needs, and keeping current
with the latest advances, applying evidence to practice, mitigating adverse
events, and identifying patients eligible to received ADCs in practice and
clinical trials are more important than ever.
This PeerView educational activity, based on a recent live symposium, offers
expert guidance on how to interpret and apply the latest evidence on HER2-,
HER3-, TROP2-targeting, and other ADCs in the treatment of different solid
tumors. Strategies for decision-making and optimizing outcomes for patients
with cancer who may benefit from ADCs are also discussed, and case-based
clinical scenarios highlight the practical considerations related to using
ADCs in real-world care settings.
Target Audience
This activity has been designed to meet the educational needs of advanced practitioners in oncology and other clinicians involved in the management of patients with solid tumors.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the rationale for use, mechanisms of action, safety and efficacy profiles based on available clinical evidence, and evolving clinical roles of the different ADCs targeting HER2, HER3, and TROP2 in solid tumors
- Identify patients with solid tumors who might benefit from HER2-, HER3-, and TROP2-targeting ADCs in clinical practice or through clinical trial enrollment
- Integrate approved and emerging therapies such as HER2-, HER3-, and TROP2-targeting ADCs safely and effectively into treatment plans of eligible patients with solid tumors according to the latest evidence and guidelines
- Implement best practices for identifying and managing treatment-related adverse events in patients with solid tumors receiving ADC therapies to promote optimal adherence, outcomes, and quality of life
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Beth Sandy, MSN, CRNP, FAPO
Thoracic Oncology Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania
Beth Sandy, MSN, CRNP, FAPO, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc. and Janssen
Pharmaceuticals, Inc.
Speakers Bureau participant with Amgen Inc.; AstraZeneca; Jazz
Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; and Takeda
Pharmaceutical Company Limited.
Faculty/Planner
Jamie Carroll, APRN, CNP, MSN
Assistant Professor of Oncology
Nurse Practitioner
Mayo Clinic
Rochester, Minnesota
Jamie Carroll, APRN, CNP, MSN, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Lilly; Novartis Pharmaceuticals
Corporation; Pfizer; Sermonix Pharmaceuticals; and Talzenna.
Speakers Bureau participant with Horizon CME
and OncLive.
Faculty/Planner
Elizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN
Senior Advanced Practice Provider
Abramson Cancer Center at Penn Presbyterian Medical Center
Philadelphia, Pennsylvania
Elizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN, has a financial
interest/relationship or affiliation in the form of:
Speakers Bureau participant with Incyte.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Nurse Practitioners
This activity is approved for 1.5 contact hour(s) of continuing education (which includes 1.0 hours of pharmacology) by the American Association of Nurse Practitioners® (AANP). Activity ID# 23106433. This activity was planned in accordance with AANP Accreditation Standards and Policies. |
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-049-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 12/9/2024. PAs should only claim credit commensurate with the extent of their participation. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CE/CPE/AAPA Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on December 9, 2024; credit is no longer available.
Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care
Media: Enduring Material
Activity Release Date: November 10, 2023
Activity Expiration Date: December 9, 2024
Time to Complete Activity: 90 minutes
Activity Description
Antibody–drug conjugates (ADCs), including those targeting HER2, HER3, and
TROP2, are an exciting new class of therapies that selectively deliver
cytotoxic payloads to cancer cells. Recent regulatory approvals have cemented
the role of ADCs in the treatment of various solid tumors, motivating further
innovation to expand their use in other tumor types and disease settings. The
new ADC era brings hope to patients with unmet needs, and keeping current
with the latest advances, applying evidence to practice, mitigating adverse
events, and identifying patients eligible to received ADCs in practice and
clinical trials are more important than ever.
This PeerView educational activity, based on a recent live symposium, offers
expert guidance on how to interpret and apply the latest evidence on HER2-,
HER3-, TROP2-targeting, and other ADCs in the treatment of different solid
tumors. Strategies for decision-making and optimizing outcomes for patients
with cancer who may benefit from ADCs are also discussed, and case-based
clinical scenarios highlight the practical considerations related to using
ADCs in real-world care settings.
Target Audience
This activity has been designed to meet the educational needs of advanced practitioners in oncology and other clinicians involved in the management of patients with solid tumors.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the rationale for use, mechanisms of action, safety and efficacy profiles based on available clinical evidence, and evolving clinical roles of the different ADCs targeting HER2, HER3, and TROP2 in solid tumors
- Identify patients with solid tumors who might benefit from HER2-, HER3-, and TROP2-targeting ADCs in clinical practice or through clinical trial enrollment
- Integrate approved and emerging therapies such as HER2-, HER3-, and TROP2-targeting ADCs safely and effectively into treatment plans of eligible patients with solid tumors according to the latest evidence and guidelines
- Implement best practices for identifying and managing treatment-related adverse events in patients with solid tumors receiving ADC therapies to promote optimal adherence, outcomes, and quality of life
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Beth Sandy, MSN, CRNP, FAPO
Thoracic Oncology Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania
Beth Sandy, MSN, CRNP, FAPO, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc. and Janssen
Pharmaceuticals, Inc.
Speakers Bureau participant with Amgen Inc.; AstraZeneca; Jazz
Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; and Takeda
Pharmaceutical Company Limited.
Faculty/Planner
Jamie Carroll, APRN, CNP, MSN
Assistant Professor of Oncology
Nurse Practitioner
Mayo Clinic
Rochester, Minnesota
Jamie Carroll, APRN, CNP, MSN, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Lilly; Novartis Pharmaceuticals
Corporation; Pfizer; Sermonix Pharmaceuticals; and Talzenna.
Speakers Bureau participant with Horizon CME
and OncLive.
Faculty/Planner
Elizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN
Senior Advanced Practice Provider
Abramson Cancer Center at Penn Presbyterian Medical Center
Philadelphia, Pennsylvania
Elizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN, has a financial
interest/relationship or affiliation in the form of:
Speakers Bureau participant with Incyte.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Nurse Practitioners
This activity is approved for 1.5 contact hour(s) of continuing education (which includes 1.0 hours of pharmacology) by the American Association of Nurse Practitioners® (AANP). Activity ID# 23106433. This activity was planned in accordance with AANP Accreditation Standards and Policies. |
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-049-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 12/9/2024. PAs should only claim credit commensurate with the extent of their participation. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CE/CPE/AAPA Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R Disease
StartThis activity expired on November 26, 2024; credit is no longer available.
Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R Disease
Media: Enduring Material
Activity Release Date: October 27, 2023
Activity Expiration Date: November 26, 2024
Time to Complete Activity: 60 minutes
Activity Description
Covalent BTK inhibitors (cBTKi) have transformed the management of mantle cell lymphoma (MCL). However, their efficacy as second-line therapies is often hindered by intolerance and treatment resistance, leading to poor outcomes for many patients with relapsed/refractory (R/R) disease who discontinue cBTKi. Are you prepared to overcome this challenge by developing evidence-based sequential strategies for MCL treatment? Find out how to “revive” the BTK target by joining two MCL experts as they explore the integration of non-covalent BTKi (ncBTKi) in sequential R/R MCL care. Throughout, the experts use robust case discussion and 3D and 2D animations to provide guidance on developing ncBTKi-inclusive treatment plans that deliver safe and highly effective care while extending the clinical benefits of BTKi therapy.
Target Audience
This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, advanced practice clinicians, nurses, pharmacists, and other clinicians involved in the management of MCL.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the latest clinical evidence, mechanistic rationale, and current guidelines supporting the use of non-covalent BTKi agents in R/R MCL settings
- Integrate non-covalent BTK inhibitors into modern sequential treatment plans for R/R MCL, including in settings of BTKi-intolerant, or -resistant disease
- Develop collaborative protocols for addressing practical aspects of MCL care, including monitoring, patient education, and management of adverse events, when using BTKi strategies
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Nirav Shah, MD, MS
Associate Professor of Medicine
Division of Hematology and Oncology
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin
Nirav Shah, MD, MS, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Bristol Myers Squibb-Juno Therapeutics
Inc; Epizyme, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Kite,
A Gilead Company; Loxo Oncology-Lilly; Miltenyi Biotec; Novartis
Pharmaceuticals Corporation; Seattle Genetics, Inc.; TG Therapeutics, Inc.;
and Umoja Biopharma.
Grant/Research Support from Loxo Oncology-Lilly and Miltenyi
Biotec.
Co-Chair/Planner
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD
Haematology Consultant
Oxford University Hospitals
NHS Foundation Trust
Oxford, United Kingdom
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene; F.
Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.;
Kite, A Gilead Company; Lilly; Loxo Oncology, Inc.; and Secura Bio,
Inc.
Grant/Research Support from AstraZeneca and BeiGene.
Speaker for AbbVie; AstraZeneca; F. Hoffmann-La Roche AG; Gilead
Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly;
and Loxo Oncology, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-064-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 11/26/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on November 26, 2024; credit is no longer available.
Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R Disease
Media: Enduring Material
Activity Release Date: October 27, 2023
Activity Expiration Date: November 26, 2024
Time to Complete Activity: 60 minutes
Activity Description
Covalent BTK inhibitors (cBTKi) have transformed the management of mantle cell lymphoma (MCL). However, their efficacy as second-line therapies is often hindered by intolerance and treatment resistance, leading to poor outcomes for many patients with relapsed/refractory (R/R) disease who discontinue cBTKi. Are you prepared to overcome this challenge by developing evidence-based sequential strategies for MCL treatment? Find out how to “revive” the BTK target by joining two MCL experts as they explore the integration of non-covalent BTKi (ncBTKi) in sequential R/R MCL care. Throughout, the experts use robust case discussion and 3D and 2D animations to provide guidance on developing ncBTKi-inclusive treatment plans that deliver safe and highly effective care while extending the clinical benefits of BTKi therapy.
Target Audience
This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, advanced practice clinicians, nurses, pharmacists, and other clinicians involved in the management of MCL.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the latest clinical evidence, mechanistic rationale, and current guidelines supporting the use of non-covalent BTKi agents in R/R MCL settings
- Integrate non-covalent BTK inhibitors into modern sequential treatment plans for R/R MCL, including in settings of BTKi-intolerant, or -resistant disease
- Develop collaborative protocols for addressing practical aspects of MCL care, including monitoring, patient education, and management of adverse events, when using BTKi strategies
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Nirav Shah, MD, MS
Associate Professor of Medicine
Division of Hematology and Oncology
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin
Nirav Shah, MD, MS, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Bristol Myers Squibb-Juno Therapeutics
Inc; Epizyme, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Kite,
A Gilead Company; Loxo Oncology-Lilly; Miltenyi Biotec; Novartis
Pharmaceuticals Corporation; Seattle Genetics, Inc.; TG Therapeutics, Inc.;
and Umoja Biopharma.
Grant/Research Support from Loxo Oncology-Lilly and Miltenyi
Biotec.
Co-Chair/Planner
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD
Haematology Consultant
Oxford University Hospitals
NHS Foundation Trust
Oxford, United Kingdom
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene; F.
Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.;
Kite, A Gilead Company; Lilly; Loxo Oncology, Inc.; and Secura Bio,
Inc.
Grant/Research Support from AstraZeneca and BeiGene.
Speaker for AbbVie; AstraZeneca; F. Hoffmann-La Roche AG; Gilead
Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly;
and Loxo Oncology, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-064-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 11/26/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application
StartThis activity expired on November 6, 2024; credit is no longer available.
FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application
Media: Enduring Material
Activity Release Date: October 7, 2023
Activity Expiration Date: November 6, 2024
Time to Complete Activity: 75 minutes
Activity Description
Advances in the understanding of the pathogenesis of generalized
myasthenia gravis (gMG), a rare, chronic autoimmune disorder, have led to the
development of new therapeutics that more selectively address the underlying
disease process compared with traditional therapies that often left patients
with substantial disease and treatment burden. These newer treatments include
Fc receptor (FcRn) inhibitors that increase immunoglobulin G (IgG)
degradation, leading to reduced levels of autoreactive IgG antibodies via
differing mechanisms of action and modes of delivery, including intravenous
infusion and subcutaneous injection.
In this PeerView “Candid Conversations and Clinical Consults” activity, a
neurologist, a clinical pharmacist, and an infusion nurse guide participants
through a case-based look at the evolving gMG treatment landscape. The
faculty share their expertise and put gMG management into practical context
through panel discussions that reflect their unique professional perspectives
as members of the gMG care team.
Target Audience
This activity has been designed to meet the educational needs of neurologists, nurse practitioners, pharmacists, infusion nurses, and other clinicians involved in the management of patients with myasthenia gravis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Assess how the safety, efficacy, and tolerability data related to newer treatment options for generalized myasthenia gravis (gMG) compare with the corresponding data for traditionally used therapies
- Demonstrate understanding of the rationale and mechanisms for reducing levels of autoreactive IgG antibodies using FcRn-modulating therapies when making gMG treatment decisions
- Implement safe, individualized administration protocols for patients using FcRn-modulating therapy, with consideration for proper infusion procedures, premedications, vaccinations, and treatment cycle timing
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
James F. Howard Jr., MD
Professor of Neurology, Medicine and Allied Health
Department of Neurology
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
James F. Howard Jr., MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; Argenx;
Biologix Pharma; F. Hoffmann-La Roche Ltd.; Horizon Therapeutics plc;
Immunovant, Inc.; Merck & Co., Inc./EMD Serono, Inc.; NMD Pharma A/S;
Novartis Pharmaceuticals Corporation; Ra Pharmaceuticals, Inc./UCB
Inc.; Regeneron Pharmaceuticals Inc.; Sanofi; Toleranzia AB; and
Zai Lab.
Grant/Research Support from Alexion Pharmaceuticals, Inc.; Argenx;
Cartesian Therapeutics, Inc.; and Ra Pharmaceuticals, Inc./UCB Inc.
Speaker for Alexion Pharmaceuticals, Inc.; Argenx; F. Hoffmann-La
Roche Ltd; and Zai Lab.
Faculty/Planner
Amy Clarke, MSN, RN, IgCN
Vice President
Clinical Nursing Practice
Optum Infusion Pharmacy
Lenexa, Kansas
Amy Clarke, MSN, RN, IgCN, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Grifols, S.A.; Kedrion Biopharma Inc.;
Koru Pharma Co., LTD; Pfizer; and Takeda Pharmaceutical Company
Limited.
Faculty/Planner
Claire Spahn, PharmD, BCPS
Clinical Pharmacist in Neurology
Stanford Neuroscience Health Center
Stanford, California
Claire Spahn, PharmD, BCPS, has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from argenx US, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.25 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-057-H01-P
Type of Activity: Application
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on November 6, 2024; credit is no longer available.
FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application
Media: Enduring Material
Activity Release Date: October 7, 2023
Activity Expiration Date: November 6, 2024
Time to Complete Activity: 75 minutes
Activity Description
Advances in the understanding of the pathogenesis of generalized
myasthenia gravis (gMG), a rare, chronic autoimmune disorder, have led to the
development of new therapeutics that more selectively address the underlying
disease process compared with traditional therapies that often left patients
with substantial disease and treatment burden. These newer treatments include
Fc receptor (FcRn) inhibitors that increase immunoglobulin G (IgG)
degradation, leading to reduced levels of autoreactive IgG antibodies via
differing mechanisms of action and modes of delivery, including intravenous
infusion and subcutaneous injection.
In this PeerView “Candid Conversations and Clinical Consults” activity, a
neurologist, a clinical pharmacist, and an infusion nurse guide participants
through a case-based look at the evolving gMG treatment landscape. The
faculty share their expertise and put gMG management into practical context
through panel discussions that reflect their unique professional perspectives
as members of the gMG care team.
Target Audience
This activity has been designed to meet the educational needs of neurologists, nurse practitioners, pharmacists, infusion nurses, and other clinicians involved in the management of patients with myasthenia gravis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Assess how the safety, efficacy, and tolerability data related to newer treatment options for generalized myasthenia gravis (gMG) compare with the corresponding data for traditionally used therapies
- Demonstrate understanding of the rationale and mechanisms for reducing levels of autoreactive IgG antibodies using FcRn-modulating therapies when making gMG treatment decisions
- Implement safe, individualized administration protocols for patients using FcRn-modulating therapy, with consideration for proper infusion procedures, premedications, vaccinations, and treatment cycle timing
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
James F. Howard Jr., MD
Professor of Neurology, Medicine and Allied Health
Department of Neurology
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
James F. Howard Jr., MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; Argenx;
Biologix Pharma; F. Hoffmann-La Roche Ltd.; Horizon Therapeutics plc;
Immunovant, Inc.; Merck & Co., Inc./EMD Serono, Inc.; NMD Pharma A/S;
Novartis Pharmaceuticals Corporation; Ra Pharmaceuticals, Inc./UCB
Inc.; Regeneron Pharmaceuticals Inc.; Sanofi; Toleranzia AB; and
Zai Lab.
Grant/Research Support from Alexion Pharmaceuticals, Inc.; Argenx;
Cartesian Therapeutics, Inc.; and Ra Pharmaceuticals, Inc./UCB Inc.
Speaker for Alexion Pharmaceuticals, Inc.; Argenx; F. Hoffmann-La
Roche Ltd; and Zai Lab.
Faculty/Planner
Amy Clarke, MSN, RN, IgCN
Vice President
Clinical Nursing Practice
Optum Infusion Pharmacy
Lenexa, Kansas
Amy Clarke, MSN, RN, IgCN, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Grifols, S.A.; Kedrion Biopharma Inc.;
Koru Pharma Co., LTD; Pfizer; and Takeda Pharmaceutical Company
Limited.
Faculty/Planner
Claire Spahn, PharmD, BCPS
Clinical Pharmacist in Neurology
Stanford Neuroscience Health Center
Stanford, California
Claire Spahn, PharmD, BCPS, has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from argenx US, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.25 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-057-H01-P
Type of Activity: Application
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
Command and Control MDS: New Science in MDS Management and Implications for Veteran-Centered Care
StartThis activity expired on October 28, 2024; credit is no longer available.
Command and Control MDS: New Science in MDS Management and Implications for Veteran-Centered Care
Media: Enduring Material
Activity Release Date: September 29, 2023
Activity Expiration Date: October 28, 2024
Time to Complete Activity: 60 minutes
Activity Description
Learn how to command and control management of MDS for your patients, including veterans who may be suffering from symptoms tied to this challenging disorder, in this PeerView Clinical Consults activity recorded at the 2023 Association of VA Hematology/Oncology Annual Meeting. Two experts in the field use conversational case discussions to provide guidance on a personalized, team-centered approach to managing MDS and use real-world scenarios to clarify the complexities of lower-risk MDS diagnosis and risk stratification, while providing guidance on how to leverage new science to overcome challenges such as anemia and transfusion dependence. Access this activity today to accelerate your practice with better outcomes, and learn how recent developments have changed the current standard of care.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists and hematologists, and other clinicians involved in the management of patients with MDS.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the symptomatology, molecular features, and risk factors associated with MDS that can inform modern diagnostic, prognostic, and management plans
- Cite updated evidence supporting the use of innovative therapeutics for the risk-adapted management of MDS
- Develop team-based, personalized management strategies for MDS that incorporate newer therapeutics, including for the frontline and subsequent management of LR-MDS with anemia
- Implement team strategies to address dosing, safety, and drug delivery considerations in the MDS setting
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Michael R. Savona, MD
Professor of Medicine and Cancer Biology
Beverly and George Rawlings Director of Hematology Research
Department of Internal Medicine
Vanderbilt University School of Medicine
Nashville, Tennessee
Michael R. Savona, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie; Bristol Myers Squibb; CTI
BioPharma Corp.; Geron; Karyopharm; Novartis Pharmaceuticals Corporation;
Ryvu Therapeutics; and Sierra Oncology, Inc.
Grant/Research Support from ALX Oncology Inc.; Astex
Pharmaceuticals; Incyte Corporation; and Takeda Pharmaceutical Company
Limited.
Stock Shareholder in Empath Biosciences; Karyopharm and Ryvu
Therapeutics.
Other Financial or Material Support from Astex Pharmaceuticals for
travel grant.
Co-Chair/Planner
Andrew M. Brunner, MD
Assistant Professor, Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Andrew M. Brunner, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Acceleron Pharma, Inc.; Bristol Myers
Squibb; Gilead Sciences, Inc.; Keros Therapeutics; LAVA Therapeutics;
Novartis Pharmaceuticals Corporation; Rigel Pharmaceuticals, Inc.; Taiho
Pharmaceutical Co., Ltd.; and Takeda Pharmaceutical Company
Limited.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-063-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 10/28/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on October 28, 2024; credit is no longer available.
Command and Control MDS: New Science in MDS Management and Implications for Veteran-Centered Care
Media: Enduring Material
Activity Release Date: September 29, 2023
Activity Expiration Date: October 28, 2024
Time to Complete Activity: 60 minutes
Activity Description
Learn how to command and control management of MDS for your patients, including veterans who may be suffering from symptoms tied to this challenging disorder, in this PeerView Clinical Consults activity recorded at the 2023 Association of VA Hematology/Oncology Annual Meeting. Two experts in the field use conversational case discussions to provide guidance on a personalized, team-centered approach to managing MDS and use real-world scenarios to clarify the complexities of lower-risk MDS diagnosis and risk stratification, while providing guidance on how to leverage new science to overcome challenges such as anemia and transfusion dependence. Access this activity today to accelerate your practice with better outcomes, and learn how recent developments have changed the current standard of care.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists and hematologists, and other clinicians involved in the management of patients with MDS.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the symptomatology, molecular features, and risk factors associated with MDS that can inform modern diagnostic, prognostic, and management plans
- Cite updated evidence supporting the use of innovative therapeutics for the risk-adapted management of MDS
- Develop team-based, personalized management strategies for MDS that incorporate newer therapeutics, including for the frontline and subsequent management of LR-MDS with anemia
- Implement team strategies to address dosing, safety, and drug delivery considerations in the MDS setting
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Michael R. Savona, MD
Professor of Medicine and Cancer Biology
Beverly and George Rawlings Director of Hematology Research
Department of Internal Medicine
Vanderbilt University School of Medicine
Nashville, Tennessee
Michael R. Savona, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie; Bristol Myers Squibb; CTI
BioPharma Corp.; Geron; Karyopharm; Novartis Pharmaceuticals Corporation;
Ryvu Therapeutics; and Sierra Oncology, Inc.
Grant/Research Support from ALX Oncology Inc.; Astex
Pharmaceuticals; Incyte Corporation; and Takeda Pharmaceutical Company
Limited.
Stock Shareholder in Empath Biosciences; Karyopharm and Ryvu
Therapeutics.
Other Financial or Material Support from Astex Pharmaceuticals for
travel grant.
Co-Chair/Planner
Andrew M. Brunner, MD
Assistant Professor, Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Andrew M. Brunner, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Acceleron Pharma, Inc.; Bristol Myers
Squibb; Gilead Sciences, Inc.; Keros Therapeutics; LAVA Therapeutics;
Novartis Pharmaceuticals Corporation; Rigel Pharmaceuticals, Inc.; Taiho
Pharmaceutical Co., Ltd.; and Takeda Pharmaceutical Company
Limited.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-063-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 10/28/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
Novel Targets for Management of Generalized Pustular Psoriasis: Utilizing a Team-Based Approach From Diagnosis to Treatment of Flares
StartThis activity expired on September 13, 2024; credit is no longer available.
Novel Targets for Management of Generalized Pustular Psoriasis: Utilizing a Team-Based Approach From Diagnosis to Treatment of Flares
Media: Enduring Material
Activity Release Date: September 14, 2023
Activity Expiration Date: September 13, 2024
Time to Complete Activity: 60 minutes
Activity Description
How much do you know about the changing therapeutic landscape and the first FDA-approved treatment for generalized pustular psoriasis (GPP)? Test your knowledge and earn credit as you get the latest evidence and expert guidance on individualizing treatment plans for patients with GPP.
Target Audience
This activity has been designed to meet the educational needs of dermatologists, emergency medicine specialists, general practitioners, family physicians, NPs, PAs, pharmacists, and other healthcare professionals involved in the care of patients with generalized pustular psoriasis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Accurately diagnose pustular psoriasis and assess the disease severity based on patient history and clinical manifestations
- Identify pathophysiological differences among generalized pustular psoriasis (GPP) and plaque psoriasis
- Evaluate novel biologic therapies for pustular psoriasis based on their efficacy, safety, and mechanism of action
- Develop effective, individualized treatment strategies for patients with GPP through patient education and shared decision-making and a multidisciplinary team-based approach
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Faculty/Planner
Boni Elizabeth Elewski, MD
Professor and Chair of Dermatology
UAB/ The University of Alabama at Birmingham
Birmingham, Alabama
Boni Elizabeth Elewski, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; Arcutis
Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals,
Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; LEO
Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho
Dermatology; and UCB, Inc.
Grant/Research Support from AbbVie Inc.; AnaptysBio,
Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers
Squibb; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.;
Lilly; Novartis Pharmaceuticals Corporation; Pfizer; and UCB,
Inc.
Honoraria from Amgen Inc.; Arcutis Biotherapeutics,
Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers
Squibb; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.;
Lilly; Novartis Pharmaceuticals Corporation; Ortho Dermatology; and UCB,
Inc.
Faculty/Planner
Mark Lebwohl, MD
Dean for Clinical Therapeutics
Professor & Chair Emeritus
Kimberly & Eric J. Waldman Department of Dermatology
Icahn School of Medicine
New York, New York
Mark Lebwohl, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AnaptysBio, Inc.; Almirall, LLC;
AltruBio; AnaptysBio, Inc.; Apogee Therapeutics; Arcutis Biotherapeutics,
Inc.; Aristea Therapeutics; Atomwise Inc.; Avotres Inc.; Boehringer
Ingelheim Pharmaceuticals, Inc.; Brickell Biotech; Bristol Myers Squibb; Cara
Therapeutics; Castle Biosciences, Inc.; Celltrion, Inc.; CorEvitas,
LLC; Dermavant Sciences, Inc.; Dr.Reddy’s; EPI Health; Evommune, Inc.;
Facilitation of International Dermatology Education; Forte Biosciences,
Inc.; Foundation for Research and Education in Dermatology; Galderma;
Genentech, Inc.; Helsinn Healthcare S.A.; Incyte; LEO Pharma Inc.; Meiji
Seika Kaisha, Ltd.; Mindera Health; National Society of Cutaneous
Medicine; Pfizer; Seanergy Dermatology Ltd; Strata; Trevi
Therapeutics; Verrica Pharmaceuticals; and Vial.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; Arcutis
Biotherapeutics, Inc.; Avotres Inc.; Boehringer Ingelheim
Pharmaceuticals, Inc.; Cara Therapeutics; Dermavant Sciences,
Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Lilly; Ortho
Dermatologics; Regeneron Pharmaceuticals Inc.; and UCB,
Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-055-H01-P
Type of Activity: Knowledge
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 9/13/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on September 13, 2024; credit is no longer available.
Novel Targets for Management of Generalized Pustular Psoriasis: Utilizing a Team-Based Approach From Diagnosis to Treatment of Flares
Media: Enduring Material
Activity Release Date: September 14, 2023
Activity Expiration Date: September 13, 2024
Time to Complete Activity: 60 minutes
Activity Description
How much do you know about the changing therapeutic landscape and the first FDA-approved treatment for generalized pustular psoriasis (GPP)? Test your knowledge and earn credit as you get the latest evidence and expert guidance on individualizing treatment plans for patients with GPP.
Target Audience
This activity has been designed to meet the educational needs of dermatologists, emergency medicine specialists, general practitioners, family physicians, NPs, PAs, pharmacists, and other healthcare professionals involved in the care of patients with generalized pustular psoriasis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Accurately diagnose pustular psoriasis and assess the disease severity based on patient history and clinical manifestations
- Identify pathophysiological differences among generalized pustular psoriasis (GPP) and plaque psoriasis
- Evaluate novel biologic therapies for pustular psoriasis based on their efficacy, safety, and mechanism of action
- Develop effective, individualized treatment strategies for patients with GPP through patient education and shared decision-making and a multidisciplinary team-based approach
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Faculty/Planner
Boni Elizabeth Elewski, MD
Professor and Chair of Dermatology
UAB/ The University of Alabama at Birmingham
Birmingham, Alabama
Boni Elizabeth Elewski, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; Arcutis
Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals,
Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; LEO
Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho
Dermatology; and UCB, Inc.
Grant/Research Support from AbbVie Inc.; AnaptysBio,
Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers
Squibb; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.;
Lilly; Novartis Pharmaceuticals Corporation; Pfizer; and UCB,
Inc.
Honoraria from Amgen Inc.; Arcutis Biotherapeutics,
Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers
Squibb; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.;
Lilly; Novartis Pharmaceuticals Corporation; Ortho Dermatology; and UCB,
Inc.
Faculty/Planner
Mark Lebwohl, MD
Dean for Clinical Therapeutics
Professor & Chair Emeritus
Kimberly & Eric J. Waldman Department of Dermatology
Icahn School of Medicine
New York, New York
Mark Lebwohl, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AnaptysBio, Inc.; Almirall, LLC;
AltruBio; AnaptysBio, Inc.; Apogee Therapeutics; Arcutis Biotherapeutics,
Inc.; Aristea Therapeutics; Atomwise Inc.; Avotres Inc.; Boehringer
Ingelheim Pharmaceuticals, Inc.; Brickell Biotech; Bristol Myers Squibb; Cara
Therapeutics; Castle Biosciences, Inc.; Celltrion, Inc.; CorEvitas,
LLC; Dermavant Sciences, Inc.; Dr.Reddy’s; EPI Health; Evommune, Inc.;
Facilitation of International Dermatology Education; Forte Biosciences,
Inc.; Foundation for Research and Education in Dermatology; Galderma;
Genentech, Inc.; Helsinn Healthcare S.A.; Incyte; LEO Pharma Inc.; Meiji
Seika Kaisha, Ltd.; Mindera Health; National Society of Cutaneous
Medicine; Pfizer; Seanergy Dermatology Ltd; Strata; Trevi
Therapeutics; Verrica Pharmaceuticals; and Vial.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; Arcutis
Biotherapeutics, Inc.; Avotres Inc.; Boehringer Ingelheim
Pharmaceuticals, Inc.; Cara Therapeutics; Dermavant Sciences,
Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Lilly; Ortho
Dermatologics; Regeneron Pharmaceuticals Inc.; and UCB,
Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-055-H01-P
Type of Activity: Knowledge
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 9/13/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
Level Up With Personalized Care for CLL/SLL: Achieving Better Total Care With Targeted Agents & Innovative Combinations
StartThis activity expired on October 6, 2024; credit is no longer available.
Level Up With Personalized Care for CLL/SLL: Achieving Better Total Care With Targeted Agents & Innovative Combinations
Media: Enduring Material
Activity Release Date: September 7, 2023
Activity Expiration Date: October 6, 2024
Time to Complete Activity: 60 minutes
Activity Description
Innovative therapeutics have transformed the management of chronic
lymphocytic leukemia (CLL) and allowed patients a greater range of treatment
options. Covalent BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i) have
demonstrated efficacy in a wide variety of treatment settings, and newer,
non-covalent BTKi are poised to overcome long-standing therapeutic standards.
Do you have the tools needed to “level up” your practice?
Find out in this “Clinical Consults” activity based on a symposium that was
recorded at the Society of Hematologic Oncology’s 11th Annual Meeting.
Throughout this program, a panel of leading CLL experts use conversational,
case-based dialogue to provide guidance on integrating modern therapeutics
anchored by BTKi and BCL2i regimens, along with rapidly emerging non-covalent
BTKi and BTKi-BCL2i combinations. Join the leading lights of CLL, sharpen
your therapeutic skills, and reach the next level of CLL care today!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other clinicians involved in the management of CLL.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Cite current evidence and updated practice guidelines supporting the use of targeted agents and emerging treatment options in CLL, such as BTK and BCL2 inhibitors, CAR-T, and bispecifics
- Develop personalized management protocols that include established and emerging targeted strategies as single-agent and combination platforms for patients with treatment-naïve CLL based on prognostic information, the presence of comorbidities, and safety considerations
- Implement sequential treatment plans with targeted options for patients with therapeutic intolerance and/or relapsed/refractory CLL
- Manage safety and care delivery considerations associated with the use of targeted agents and other newer therapeutics in the CLL setting
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent educational grants from AstraZeneca; BeiGene; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Lilly.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education
activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-089-H01-P
Type of Activity: Application
Faculty Disclosures
Co-Chair/Planner
William G. Wierda, MD, PhD
Professor, Department of Leukemia, Division of Cancer Medicine
Jane and John Justin Distinguished Chair in Leukemia Research in Honor of Dr.
Elihu Estey
Section Chief - Chronic Lymphocytic Leukemia
Center Medical Director, Leukemia
Executive Medical Director, Inpatient Medical Services
The University of Texas MD Anderson Cancer Center
Houston, Texas
William G. Wierda, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Grant/Research Support from AbbVie; Acerta Pharma; Accutar Biotech;
Bristol Myers Squibb; Cyclacel Pharmaceuticals Inc.; Genentech, Inc.; Gilead
Sciences, Inc.; GlaxoSmithKline; Janssen Biotech, Inc.; Juno Pharmaceuticals;
Kite, A Gilead Company; Loxo Oncology, Inc.; miRagen Therapeutics, Inc.
(ended); Novartis Pharmaceuticals Corporation; Numab Therapeutics AG; Nurix
Therapeutics, Inc.; Oncternal Therapeutics; Pharmacyclics, Inc.; Sunesis
Pharmaceuticals, Inc. (ended); and Xencor.
Other Financial or Material Support for Nonrelevant Financial
Relationship: National Comprehensive Cancer Network (Chair & CLL); NIH/NCI
under award number P30 CA016672 and used MDACC Cancer Center Support Grant
(CCSG) shared resources.
Co-Chair/Planner
Nicole Lamanna, MD
Professor of Medicine, Leukemia Service
Director of the Chronic Lymphocytic Leukemia Program
Hematologic Malignancies Section
Herbert Irving Comprehensive Cancer Center
New York-Presbyterian/Columbia University Medical Center
New York, New York
Nicole Lamanna, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies;
AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.;
and Pharmacyclics LLC.
Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.;
Genentech, Inc.; Lilly/Loxo Oncology; MingSight Pharmaceuticals, Inc.;
Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics,
Inc.
Faculty/Planner
Meghan C. Thompson, MD
Assistant Attending L1, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, New York
Meghan C. Thompson, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Lilly/LOXO Oncology;
Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.
Grant/Research Support from AbbVie; AstraZeneca; BeiGene,
Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics. Research
funding goes to Institution.
Honoraria from Brazilian Association of Hematology; Dava
Oncology; Curio Science; Hemotherapy and Cellular Therapy (ABHH);
Massachusetts Medical Society; MJH Life Sciences; Intellisphere LLC; Phillips
Group Oncology Communications; and VJHemOnc.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
For pharmacists, upon receipt of the completed activity evaluation, you will
receive an email from email@email.peerviewpress.com within 2 weeks. MLI will
accept your completed evaluation form for up to 30 days and will
report your participation to the NABP only if you provide your NABP
e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your
participation record at the NABP website: https://nabp.pharmacy/.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity’s topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on October 6, 2024; credit is no longer available.
Level Up With Personalized Care for CLL/SLL: Achieving Better Total Care With Targeted Agents & Innovative Combinations
Media: Enduring Material
Activity Release Date: September 7, 2023
Activity Expiration Date: October 6, 2024
Time to Complete Activity: 60 minutes
Activity Description
Innovative therapeutics have transformed the management of chronic
lymphocytic leukemia (CLL) and allowed patients a greater range of treatment
options. Covalent BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i) have
demonstrated efficacy in a wide variety of treatment settings, and newer,
non-covalent BTKi are poised to overcome long-standing therapeutic standards.
Do you have the tools needed to “level up” your practice?
Find out in this “Clinical Consults” activity based on a symposium that was
recorded at the Society of Hematologic Oncology’s 11th Annual Meeting.
Throughout this program, a panel of leading CLL experts use conversational,
case-based dialogue to provide guidance on integrating modern therapeutics
anchored by BTKi and BCL2i regimens, along with rapidly emerging non-covalent
BTKi and BTKi-BCL2i combinations. Join the leading lights of CLL, sharpen
your therapeutic skills, and reach the next level of CLL care today!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other clinicians involved in the management of CLL.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Cite current evidence and updated practice guidelines supporting the use of targeted agents and emerging treatment options in CLL, such as BTK and BCL2 inhibitors, CAR-T, and bispecifics
- Develop personalized management protocols that include established and emerging targeted strategies as single-agent and combination platforms for patients with treatment-naïve CLL based on prognostic information, the presence of comorbidities, and safety considerations
- Implement sequential treatment plans with targeted options for patients with therapeutic intolerance and/or relapsed/refractory CLL
- Manage safety and care delivery considerations associated with the use of targeted agents and other newer therapeutics in the CLL setting
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent educational grants from AstraZeneca; BeiGene; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Lilly.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education
activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-089-H01-P
Type of Activity: Application
Faculty Disclosures
Co-Chair/Planner
William G. Wierda, MD, PhD
Professor, Department of Leukemia, Division of Cancer Medicine
Jane and John Justin Distinguished Chair in Leukemia Research in Honor of Dr.
Elihu Estey
Section Chief - Chronic Lymphocytic Leukemia
Center Medical Director, Leukemia
Executive Medical Director, Inpatient Medical Services
The University of Texas MD Anderson Cancer Center
Houston, Texas
William G. Wierda, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Grant/Research Support from AbbVie; Acerta Pharma; Accutar Biotech;
Bristol Myers Squibb; Cyclacel Pharmaceuticals Inc.; Genentech, Inc.; Gilead
Sciences, Inc.; GlaxoSmithKline; Janssen Biotech, Inc.; Juno Pharmaceuticals;
Kite, A Gilead Company; Loxo Oncology, Inc.; miRagen Therapeutics, Inc.
(ended); Novartis Pharmaceuticals Corporation; Numab Therapeutics AG; Nurix
Therapeutics, Inc.; Oncternal Therapeutics; Pharmacyclics, Inc.; Sunesis
Pharmaceuticals, Inc. (ended); and Xencor.
Other Financial or Material Support for Nonrelevant Financial
Relationship: National Comprehensive Cancer Network (Chair & CLL); NIH/NCI
under award number P30 CA016672 and used MDACC Cancer Center Support Grant
(CCSG) shared resources.
Co-Chair/Planner
Nicole Lamanna, MD
Professor of Medicine, Leukemia Service
Director of the Chronic Lymphocytic Leukemia Program
Hematologic Malignancies Section
Herbert Irving Comprehensive Cancer Center
New York-Presbyterian/Columbia University Medical Center
New York, New York
Nicole Lamanna, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies;
AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.;
and Pharmacyclics LLC.
Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.;
Genentech, Inc.; Lilly/Loxo Oncology; MingSight Pharmaceuticals, Inc.;
Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics,
Inc.
Faculty/Planner
Meghan C. Thompson, MD
Assistant Attending L1, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, New York
Meghan C. Thompson, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Lilly/LOXO Oncology;
Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.
Grant/Research Support from AbbVie; AstraZeneca; BeiGene,
Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics. Research
funding goes to Institution.
Honoraria from Brazilian Association of Hematology; Dava
Oncology; Curio Science; Hemotherapy and Cellular Therapy (ABHH);
Massachusetts Medical Society; MJH Life Sciences; Intellisphere LLC; Phillips
Group Oncology Communications; and VJHemOnc.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
For pharmacists, upon receipt of the completed activity evaluation, you will
receive an email from email@email.peerviewpress.com within 2 weeks. MLI will
accept your completed evaluation form for up to 30 days and will
report your participation to the NABP only if you provide your NABP
e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your
participation record at the NABP website: https://nabp.pharmacy/.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity’s topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
Expanding the Circle of Personalized AML Treatment: Expert Consults on Integrating Precision Medicine With Innovative Treatment Platforms
StartThis activity expired on October 6, 2024; credit is no longer available.
Expanding the Circle of Personalized AML Treatment: Expert Consults on Integrating Precision Medicine With Innovative Treatment Platforms
Media: Enduring Material
Activity Release Date: September 7, 2023
Activity Expiration Date: October 6, 2024
Time to Complete Activity: 60 minutes
Activity Description
In recent years, the “circle” of personalized disease management for acute myeloid leukemia (AML) has been expanded, and clinicians are now able to utilize innovative therapeutics, such as novel cytotoxic platforms, targeted agents, immunotherapy, and epigenetic approaches, that can be tailored to patients’ diverse medical needs. This Clinical Consults activity pairs rapid-fire, case-based discussions with mini lecture sessions wherein the experts support their treatment recommendations by presenting the evidence that supports the use of cutting-edge therapeutics—including newer FLT3 inhibitors, chemo-free targeted platforms, epigenetic agents, and emerging antibody platforms —in various AML settings. Join the experts and learn how you can successfully “expand the circle” of personalized care in AML!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other clinicians involved in the management of AML.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Cite baseline factors such as age, comorbidities, functional status, and cytogenetic/mutational findings that can inform personalized treatment selection in AML
- Describe evidence supporting the personalized use of newer cytotoxic platforms, targeted agents, immunotherapy, radioimmunoconjugates, and epigenetic strategies as upfront treatment, maintenance therapy, or in the management of R/R AML
- Develop personalized team-based management protocols for AML that integrate newer treatment modalities based on the presence or absence of targetable mutations, functional status, treatment setting, or subtype
- Manage optimized dosing, response monitoring, and safety considerations when using modern therapeutic platforms in the AML setting
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through educational grants from Actinium Pharmaceuticals, Astellas, and Bristol Myers Squibb.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education
activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-091-H01-P
Type of Activity: Application
Faculty Disclosures
Co-Chair/Planner
Naval Daver, MD
Director, Leukemia Research Alliance Program
Professor
Department of Leukemia, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Naval Daver, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals, Inc.;
Amgen Inc.; AROG Pharmaceuticals, INC.; Astellas Pharma Inc.; Bristol Myers
Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; Genentech, Inc.; Gilead
Sciences, Inc.; ImmunoGen, Inc.; Jazz Pharmaceuticals, Inc.; Kite, A Gilead
Company; Novartis Pharmaceuticals Corporation; Pfizer; Servier
Pharmaceuticals LLC; Shattuck Labs, Inc.; Stemline Therapeutics/Menarini
Group; Syndax Pharmaceuticals Inc.; and Trillium Therapeutics Inc.
Grant/Research Support from AbbVie; Amgen Inc.; Astellas Pharma
Inc.; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Fate Therapeutics;
Genentech, Inc.; Gilead Sciences, Inc.; GlycoMimetics, Inc.; Hanmi
Pharmaceutical Co., Ltd.; ImmunoGen, Inc.; Kite, A Gilead Company; NovImmune
SA; Pfizer; Servier Pharmaceuticals LLC; Trillium Therapeutics Inc.; and
TrovaGene, Inc. Research funding goes to institution.
Co-Chair/Planner
Gail J. Roboz, MD
William S. Paley Professor of Medicine
Director, Clinical and Translational Leukemia Programs
Weill Cornell Medicine
The New York Presbyterian Hospital
New York, New York
Gail J. Roboz, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AbbVie; Amgen Inc.; Argenx;
AstraZeneca; bluebird bio, Inc.; Blueprint Medicines; Bristol Myers Squibb;
Caribou Biosciences; Celgene Corporation; Daiichi Sankyo, Inc.; Ellipses
Pharma; F. Hoffmann-La Roche AG; GlaxoSmithKline; Janssen Pharmaceuticals,
Inc; Jasper Therapeutics, Inc.; Jazz Pharmaceuticals, Inc.; Molecular
Partners; Novartis Pharmaceuticals Corporation; Pfizer; Syndax
Pharmaceuticals Inc.; Takeda Pharmaceutical Company Limited (IRC Chair); and
Telix Pharma.
Grant/Research Support from Janssen Pharmaceuticals, Inc.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
For pharmacists, upon receipt of the completed activity evaluation, you will
receive an email from email@email.peerviewpress.com within 2 weeks. MLI will
accept your completed evaluation form for up to 30 days and will
report your participation to the NABP only if you provide your NABP
e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your
participation record at the NABP website: https://nabp.pharmacy/.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity’s topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on October 6, 2024; credit is no longer available.
Expanding the Circle of Personalized AML Treatment: Expert Consults on Integrating Precision Medicine With Innovative Treatment Platforms
Media: Enduring Material
Activity Release Date: September 7, 2023
Activity Expiration Date: October 6, 2024
Time to Complete Activity: 60 minutes
Activity Description
In recent years, the “circle” of personalized disease management for acute myeloid leukemia (AML) has been expanded, and clinicians are now able to utilize innovative therapeutics, such as novel cytotoxic platforms, targeted agents, immunotherapy, and epigenetic approaches, that can be tailored to patients’ diverse medical needs. This Clinical Consults activity pairs rapid-fire, case-based discussions with mini lecture sessions wherein the experts support their treatment recommendations by presenting the evidence that supports the use of cutting-edge therapeutics—including newer FLT3 inhibitors, chemo-free targeted platforms, epigenetic agents, and emerging antibody platforms —in various AML settings. Join the experts and learn how you can successfully “expand the circle” of personalized care in AML!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other clinicians involved in the management of AML.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Cite baseline factors such as age, comorbidities, functional status, and cytogenetic/mutational findings that can inform personalized treatment selection in AML
- Describe evidence supporting the personalized use of newer cytotoxic platforms, targeted agents, immunotherapy, radioimmunoconjugates, and epigenetic strategies as upfront treatment, maintenance therapy, or in the management of R/R AML
- Develop personalized team-based management protocols for AML that integrate newer treatment modalities based on the presence or absence of targetable mutations, functional status, treatment setting, or subtype
- Manage optimized dosing, response monitoring, and safety considerations when using modern therapeutic platforms in the AML setting
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through educational grants from Actinium Pharmaceuticals, Astellas, and Bristol Myers Squibb.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education
activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-091-H01-P
Type of Activity: Application
Faculty Disclosures
Co-Chair/Planner
Naval Daver, MD
Director, Leukemia Research Alliance Program
Professor
Department of Leukemia, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Naval Daver, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals, Inc.;
Amgen Inc.; AROG Pharmaceuticals, INC.; Astellas Pharma Inc.; Bristol Myers
Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; Genentech, Inc.; Gilead
Sciences, Inc.; ImmunoGen, Inc.; Jazz Pharmaceuticals, Inc.; Kite, A Gilead
Company; Novartis Pharmaceuticals Corporation; Pfizer; Servier
Pharmaceuticals LLC; Shattuck Labs, Inc.; Stemline Therapeutics/Menarini
Group; Syndax Pharmaceuticals Inc.; and Trillium Therapeutics Inc.
Grant/Research Support from AbbVie; Amgen Inc.; Astellas Pharma
Inc.; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Fate Therapeutics;
Genentech, Inc.; Gilead Sciences, Inc.; GlycoMimetics, Inc.; Hanmi
Pharmaceutical Co., Ltd.; ImmunoGen, Inc.; Kite, A Gilead Company; NovImmune
SA; Pfizer; Servier Pharmaceuticals LLC; Trillium Therapeutics Inc.; and
TrovaGene, Inc. Research funding goes to institution.
Co-Chair/Planner
Gail J. Roboz, MD
William S. Paley Professor of Medicine
Director, Clinical and Translational Leukemia Programs
Weill Cornell Medicine
The New York Presbyterian Hospital
New York, New York
Gail J. Roboz, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AbbVie; Amgen Inc.; Argenx;
AstraZeneca; bluebird bio, Inc.; Blueprint Medicines; Bristol Myers Squibb;
Caribou Biosciences; Celgene Corporation; Daiichi Sankyo, Inc.; Ellipses
Pharma; F. Hoffmann-La Roche AG; GlaxoSmithKline; Janssen Pharmaceuticals,
Inc; Jasper Therapeutics, Inc.; Jazz Pharmaceuticals, Inc.; Molecular
Partners; Novartis Pharmaceuticals Corporation; Pfizer; Syndax
Pharmaceuticals Inc.; Takeda Pharmaceutical Company Limited (IRC Chair); and
Telix Pharma.
Grant/Research Support from Janssen Pharmaceuticals, Inc.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
For pharmacists, upon receipt of the completed activity evaluation, you will
receive an email from email@email.peerviewpress.com within 2 weeks. MLI will
accept your completed evaluation form for up to 30 days and will
report your participation to the NABP only if you provide your NABP
e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your
participation record at the NABP website: https://nabp.pharmacy/.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity’s topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
The Commanding Heights of MDS Care: Team Strategies for Delivering Modern Personalized Therapy
StartThis activity expired on October 6, 2024; credit is no longer available.
The Commanding Heights of MDS Care: Team Strategies for Delivering Modern Personalized Therapy
Media: Enduring Material
Activity Release Date: September 7, 2023
Activity Expiration Date: October 6, 2024
Time to Complete Activity: 60 minutes
Activity Description
Myelodysplastic syndromes (MDS) encompass a diverse group of myeloid malignancies, and new data are changing what can be considered “optimal” care. In this “Seminar and Workshop” activity, two hematology-oncology experts employ case-centric discussions to provide experienced instruction on the changing nature of individualized care for patients with MDS. This activity includes updated evidence supporting the use of innovative therapies for first-line management of MDS anemia, how to treat patients with ESA-refractory MDS, and treatment strategies for individuals presenting with high-risk mutations or cytogenetics. Watch now and take your treatment plans for patients with MDS to new heights!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other team-based clinicians involved in the management of MDS.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Cite clinical, cytogenetic, and molecular features that can inform timely, accurate diagnosis and prognosis in the MDS setting
- Describe the evidence that supports the use of innovative therapeutics, including erythroid maturation agents, telomerase inhibitors, hypomethylating agent platforms, BCL2 inhibitors, and immunotherapy, in the management of patients with low-risk or high-risk MDS
- Develop personalized MDS treatment protocols for the first-line management of anemia, in the ESA-refractory setting, and for patients presenting with high-risk MDS subtypes
- Address practical aspects of modern MDS therapy, including appropriate dose selection, response monitoring, and therapy-related adverse events management
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This educational activity is supported through educational grants from Bristol Myers Squibb, Geron, and Novartis Pharmaceuticals Corporation.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education
activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-088-H01-P
Type of Activity: Knowledge
Faculty Disclosures
Co-Chair/Planner
Guillermo Garcia-Manero, MD
McCredie Professor of Medicine
Chief, Section of MDS
Vice Chair, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas
Guillermo Garcia-Manero, MD, has no financial interests/relationships or affiliations in relation to this activity.
Co-Chair/Planner
Amy E. DeZern, MD, MHS
Professor of Oncology
Division of Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center
The Johns Hopkins University School of Medicine
Baltimore, Maryland
Amy E. DeZern, MD, MHS, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Caribou
Biosciences; Geron; Gilead Sciences, Inc.; Novartis Pharmaceuticals
Corporation; Regeneron Pharmaceuticals; and Sobi.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
For pharmacists, upon receipt of the completed activity evaluation, you will
receive an email from email@email.peerviewpress.com within 2 weeks. MLI will
accept your completed evaluation form for up to 30 days and will
report your participation to the NABP only if you provide your NABP
e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your
participation record at the NABP website: https://nabp.pharmacy/.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity’s topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on October 6, 2024; credit is no longer available.
The Commanding Heights of MDS Care: Team Strategies for Delivering Modern Personalized Therapy
Media: Enduring Material
Activity Release Date: September 7, 2023
Activity Expiration Date: October 6, 2024
Time to Complete Activity: 60 minutes
Activity Description
Myelodysplastic syndromes (MDS) encompass a diverse group of myeloid malignancies, and new data are changing what can be considered “optimal” care. In this “Seminar and Workshop” activity, two hematology-oncology experts employ case-centric discussions to provide experienced instruction on the changing nature of individualized care for patients with MDS. This activity includes updated evidence supporting the use of innovative therapies for first-line management of MDS anemia, how to treat patients with ESA-refractory MDS, and treatment strategies for individuals presenting with high-risk mutations or cytogenetics. Watch now and take your treatment plans for patients with MDS to new heights!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other team-based clinicians involved in the management of MDS.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Cite clinical, cytogenetic, and molecular features that can inform timely, accurate diagnosis and prognosis in the MDS setting
- Describe the evidence that supports the use of innovative therapeutics, including erythroid maturation agents, telomerase inhibitors, hypomethylating agent platforms, BCL2 inhibitors, and immunotherapy, in the management of patients with low-risk or high-risk MDS
- Develop personalized MDS treatment protocols for the first-line management of anemia, in the ESA-refractory setting, and for patients presenting with high-risk MDS subtypes
- Address practical aspects of modern MDS therapy, including appropriate dose selection, response monitoring, and therapy-related adverse events management
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This educational activity is supported through educational grants from Bristol Myers Squibb, Geron, and Novartis Pharmaceuticals Corporation.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education
activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-088-H01-P
Type of Activity: Knowledge
Faculty Disclosures
Co-Chair/Planner
Guillermo Garcia-Manero, MD
McCredie Professor of Medicine
Chief, Section of MDS
Vice Chair, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas
Guillermo Garcia-Manero, MD, has no financial interests/relationships or affiliations in relation to this activity.
Co-Chair/Planner
Amy E. DeZern, MD, MHS
Professor of Oncology
Division of Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center
The Johns Hopkins University School of Medicine
Baltimore, Maryland
Amy E. DeZern, MD, MHS, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Caribou
Biosciences; Geron; Gilead Sciences, Inc.; Novartis Pharmaceuticals
Corporation; Regeneron Pharmaceuticals; and Sobi.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
For pharmacists, upon receipt of the completed activity evaluation, you will
receive an email from email@email.peerviewpress.com within 2 weeks. MLI will
accept your completed evaluation form for up to 30 days and will
report your participation to the NABP only if you provide your NABP
e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your
participation record at the NABP website: https://nabp.pharmacy/.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity’s topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
Setting New Expectations in Multiple Myeloma: Guidance on BCMA CAR-T & Antibody Options to Enhance Patient Care
StartThis activity expired on October 6, 2024; credit is no longer available.
Setting New Expectations in Multiple Myeloma: Guidance on BCMA CAR-T & Antibody Options to Enhance Patient Care
Media: Enduring Material
Activity Release Date: September 7, 2023
Activity Expiration Date: October 6, 2024
Time to Complete Activity: 60 minutes
Activity Description
Find out if you are prepared to select the best care for your patients with multiple myeloma (MM) in this activity based on a symposium that was recorded at the Society of Hematologic Oncology’s 11th Annual Meeting. Join the MM experts as they workshop real-world issues of integrating anti-BCMA options into MM care while also providing solutions designed to speed up the integration of CAR-T and antibody platforms into patient management. Each interactive discussion will cover BCMA CAR-T platforms, antibody-drug conjugates, and BCMA and non-BCMA bispecifics, and feature supporting evidence on earlier use of cellular therapy; the role of CAR-T and bispecific antibodies in early and later relapse; and next steps for the sequential use of “off-the-shelf” immunotherapy. Access this video activity today and see if you are prepared to enhance patient care with the latest BCMA and non-BCMA treatment options!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other clinicians involved in the management of multiple myeloma.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the mechanisms of action and latest clinical evidence supporting the use of established and emerging BCMA-targeting platforms, including bispecific antibodies and CAR-T therapy, across several lines of therapy in MM
- Select anti-BCMA options when developing personalized treatment plans for MM based on patient preference, disease prognosis, and functional status, among other considerations
- Manage practical considerations associated with BCMA therapy, including planning for referral to specialized care, consideration of off-the-shelf therapy, safety, patient education, and coordination of care
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent medical educational grants from GSK, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and, Regeneron Pharmaceuticals, Inc.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education
activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-090-H01-P
Type of Activity: Application
Faculty Disclosures
Co-Chair/Planner
Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia
Sagar Lonial, MD, FACP, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; Bristol Myers Squibb;
Celgene Corporation; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Novartis
Pharmaceuticals Corporation; Pfizer; and Takeda Pharmaceutical Company
Limited.
Grant/Research Support from Bristol Myers Squibb; Janssen
Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Takeda
Pharmaceutical Company Limited.
Stock Shareholder in TG Therapeutics.
Co-Chair/Planner
Krina Patel, MD, MSc
Associate Professor, Department of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Krina Patel, MD, MSc, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; Bristol Myers
Squibb; Celgene Corporation; Curio Bioscience; Janssen Pharmaceuticals, Inc.;
Karyopharm; Legend Biotech; Merck & Co., Inc.; Oncopeptides; Pfizer; and
Precision BioSciences, Inc.
Grant/Research Support from AbbVie; Allogene Therapeutics, Inc.;
Arcellx; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen
Pharmaceuticals, Inc.; Nektar Therapeutic; Poseida Therapeutics; Precision
BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
For pharmacists, upon receipt of the completed activity evaluation, you will
receive an email from email@email.peerviewpress.com within 2 weeks. MLI will
accept your completed evaluation form for up to 30 days and will
report your participation to the NABP only if you provide your NABP
e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your
participation record at the NABP website: https://nabp.pharmacy/.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity’s topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on October 6, 2024; credit is no longer available.
Setting New Expectations in Multiple Myeloma: Guidance on BCMA CAR-T & Antibody Options to Enhance Patient Care
Media: Enduring Material
Activity Release Date: September 7, 2023
Activity Expiration Date: October 6, 2024
Time to Complete Activity: 60 minutes
Activity Description
Find out if you are prepared to select the best care for your patients with multiple myeloma (MM) in this activity based on a symposium that was recorded at the Society of Hematologic Oncology’s 11th Annual Meeting. Join the MM experts as they workshop real-world issues of integrating anti-BCMA options into MM care while also providing solutions designed to speed up the integration of CAR-T and antibody platforms into patient management. Each interactive discussion will cover BCMA CAR-T platforms, antibody-drug conjugates, and BCMA and non-BCMA bispecifics, and feature supporting evidence on earlier use of cellular therapy; the role of CAR-T and bispecific antibodies in early and later relapse; and next steps for the sequential use of “off-the-shelf” immunotherapy. Access this video activity today and see if you are prepared to enhance patient care with the latest BCMA and non-BCMA treatment options!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other clinicians involved in the management of multiple myeloma.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the mechanisms of action and latest clinical evidence supporting the use of established and emerging BCMA-targeting platforms, including bispecific antibodies and CAR-T therapy, across several lines of therapy in MM
- Select anti-BCMA options when developing personalized treatment plans for MM based on patient preference, disease prognosis, and functional status, among other considerations
- Manage practical considerations associated with BCMA therapy, including planning for referral to specialized care, consideration of off-the-shelf therapy, safety, patient education, and coordination of care
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent medical educational grants from GSK, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and, Regeneron Pharmaceuticals, Inc.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education
activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-090-H01-P
Type of Activity: Application
Faculty Disclosures
Co-Chair/Planner
Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia
Sagar Lonial, MD, FACP, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; Bristol Myers Squibb;
Celgene Corporation; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Novartis
Pharmaceuticals Corporation; Pfizer; and Takeda Pharmaceutical Company
Limited.
Grant/Research Support from Bristol Myers Squibb; Janssen
Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Takeda
Pharmaceutical Company Limited.
Stock Shareholder in TG Therapeutics.
Co-Chair/Planner
Krina Patel, MD, MSc
Associate Professor, Department of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Krina Patel, MD, MSc, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; Bristol Myers
Squibb; Celgene Corporation; Curio Bioscience; Janssen Pharmaceuticals, Inc.;
Karyopharm; Legend Biotech; Merck & Co., Inc.; Oncopeptides; Pfizer; and
Precision BioSciences, Inc.
Grant/Research Support from AbbVie; Allogene Therapeutics, Inc.;
Arcellx; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen
Pharmaceuticals, Inc.; Nektar Therapeutic; Poseida Therapeutics; Precision
BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
For pharmacists, upon receipt of the completed activity evaluation, you will
receive an email from email@email.peerviewpress.com within 2 weeks. MLI will
accept your completed evaluation form for up to 30 days and will
report your participation to the NABP only if you provide your NABP
e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your
participation record at the NABP website: https://nabp.pharmacy/.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity’s topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
Road Map to Re-Engagement: A Visual Guide to Overcoming Individual and Systemic Barriers to HIV Care and Treatment
StartThis activity expired on August 2, 2024; credit is no longer available.
Road Map to Re-Engagement: A Visual Guide to Overcoming Individual and Systemic Barriers to HIV Care and Treatment
Media: Enduring Material
Activity Release Date: August 3, 2023
Activity Expiration Date: August 2, 2024
Time to Complete Activity:
- 45 minutes
Activity Description
In this activity, an expert discusses the factors that contribute to people living with HIV (PLWH) falling out of care, the barriers associated with different strategies for re-engaging PLWH, and individualized plans that can be used for re-engaging PLWH back into care.
Target Audience
This activity has been designed to meet the educational needs of primary care providers, HIV care providers, infectious disease providers, HIV workforce professionals, and other clinicians involved in the care of patients with HIV.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Identify individual and structural factors that contribute to PLWH falling out of care
- Discuss methodologies, benefits, and limitations associated with different strategies for re-engaging PLWH who are out of care
- Employ individualized and comprehensive plans to successfully re-engage PLWH in care
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Babafemi O. Taiwo, MBBS
Chief of Infectious Diseases in the Department of Medicine
Gene Stollerman Professor of Medicine
Professor of Medicine (Infectious Diseases)
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Babafemi O. Taiwo, MBBS, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; Johnson &
Johnson; Merck & Co., Inc.; and ViiV Healthcare.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthHIV. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Partners
This activity has been developed in partnership with HealthHIV
Support
This activity is supported by an educational grant from Gilead Sciences, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and no contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-047-H02-P
Type of Activity:
Health Education Specialists
Sponsored by PVI, PeerView Institute for Medical Education, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 0.75 total Category 1 continuing education contact hours. Maximum advanced-level continuing education contact hours are 0.0. Continuing Competency credits available are 0.0.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/CECH Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on August 2, 2024; credit is no longer available.
Road Map to Re-Engagement: A Visual Guide to Overcoming Individual and Systemic Barriers to HIV Care and Treatment
Media: Enduring Material
Activity Release Date: August 3, 2023
Activity Expiration Date: August 2, 2024
Time to Complete Activity:
- 45 minutes
Activity Description
In this activity, an expert discusses the factors that contribute to people living with HIV (PLWH) falling out of care, the barriers associated with different strategies for re-engaging PLWH, and individualized plans that can be used for re-engaging PLWH back into care.
Target Audience
This activity has been designed to meet the educational needs of primary care providers, HIV care providers, infectious disease providers, HIV workforce professionals, and other clinicians involved in the care of patients with HIV.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Identify individual and structural factors that contribute to PLWH falling out of care
- Discuss methodologies, benefits, and limitations associated with different strategies for re-engaging PLWH who are out of care
- Employ individualized and comprehensive plans to successfully re-engage PLWH in care
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Babafemi O. Taiwo, MBBS
Chief of Infectious Diseases in the Department of Medicine
Gene Stollerman Professor of Medicine
Professor of Medicine (Infectious Diseases)
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Babafemi O. Taiwo, MBBS, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; Johnson &
Johnson; Merck & Co., Inc.; and ViiV Healthcare.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthHIV. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Partners
This activity has been developed in partnership with HealthHIV
Support
This activity is supported by an educational grant from Gilead Sciences, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and no contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-047-H02-P
Type of Activity:
Health Education Specialists
Sponsored by PVI, PeerView Institute for Medical Education, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 0.75 total Category 1 continuing education contact hours. Maximum advanced-level continuing education contact hours are 0.0. Continuing Competency credits available are 0.0.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/CECH Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView